Page last updated: 2024-08-03 03:04:26

cholecystokinin

Description

Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety. [MeSH]

Cross-References

ID SourceID
PubMed CID16129670
SCHEMBL ID3045554
MeSH IDM0004235

Synonyms (10)

Synonym
gtpl860
cck-33
cholecystokinin
ccris 3307
9011-97-6
cholecystokinin 33
00xi8w60qf ,
unii-00xi8w60qf
cecekin vitrum
SCHEMBL3045554

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346883Human CCK2 receptor (Cholecystokinin receptors)1993The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24
ISSN: 0021-9258
Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin.
AID1346809Rat CCK1 receptor (Cholecystokinin receptors)1980Proceedings of the National Academy of Sciences of the United States of America, Nov, Volume: 77, Issue:11
ISSN: 0027-8424
Distinct cholecystokinin receptors in brain and pancreas.

Research

Studies (10,427)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904911 (47.10)18.7374
1990's2766 (26.53)18.2507
2000's1548 (14.85)29.6817
2010's947 (9.08)24.3611
2020's255 (2.45)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials466 (4.27%)5.53%
Reviews1,089 (9.98%)6.00%
Case Studies61 (0.56%)4.05%
Observational6 (0.05%)0.25%
Other9,292 (85.14%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
sincalideoligopeptide1993199331.0low001000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2-keto-4-methylvalerate2-oxo monocarboxylic acid;
branched-chain keto acid
algal metabolite;
human metabolite
1984198639.0low020000
phosphoserinenon-proteinogenic alpha-amino acid;
O-phosphoamino acid;
serine derivative
human metabolite2007200717.0low000100
gamma-aminobutyric acidamino acid zwitterion;
gamma-amino acid;
monocarboxylic acid
human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
1979202324.0low0285452203
5-aminovaleric acidamino acid zwitterion;
delta-amino acid;
omega-amino fatty acid
human metabolite1987198737.0low010000
5-hydroxytryptophanhydroxytryptophanhuman metabolite;
neurotransmitter
1967201336.0low021010
acetic acidmonocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
1986202120.2low010201
acetaldehydealdehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent
1985198738.0low020000
acetoneketone body;
methyl ketone;
propanones;
volatile organic compound
EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
1969201030.3low010200
ammonium hydroxideazane;
gas molecular entity;
mononuclear parent hydride
EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
1983199136.6low041000
quinacrineacridines;
aromatic ether;
organochlorine compound;
tertiary amino compound
antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
2008200816.0low000100
beta-alanineamino acid zwitterion;
beta-amino acid
agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
1989198935.0low010000
butyric acidfatty acid 4:0;
straight-chain saturated fatty acid
human urinary metabolite;
Mycoplasma genitalium metabolite
1983200132.0low010100
carbamatesamino-acid anion1971201532.4low031210
formic acidmonocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent
1994199430.0low001000
carnitineamino-acid betainehuman metabolite;
mouse metabolite
1964196460.0low010000
cholinecholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
1966199543.9low0122000
citric acid, anhydroustricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
1987199334.7low021000
chlorinehalide anion;
monoatomic chlorine
cofactor;
Escherichia coli metabolite;
human metabolite
1963201042.2low06815800
hydrochloric acidchlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride
mouse metabolite1967199944.9low2469000
salicylic acidmonohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
1995199529.0low001000
gallic acidtrihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
1970201435.0low020010
octanoic acidmedium-chain fatty acid;
straight-chain saturated fatty acid
antibacterial agent;
Escherichia coli metabolite;
human metabolite
2002201216.2low300310
3-hydroxybutyric acid(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid
human metabolite1984202021.2low210210
bupropionaromatic ketone;
monochlorobenzenes;
secondary amino compound
antidepressant;
environmental contaminant;
xenobiotic
2008200816.0low000100
3,4-dihydroxyphenylacetic acidcatechols;
dihydroxyphenylacetic acid
human metabolite1984200130.1low0211100
creatineglycine derivative;
guanidines;
zwitterion
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
1962197953.5low020000
lactic acid2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
1985201524.2low224220
diacetylalpha-diketoneEscherichia coli metabolite;
Saccharomyces cerevisiae metabolite
2000200024.0low001000
dimethyl sulfoxidesulfoxide;
volatile organic compound
alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
1986200231.6low025100
formaldehydealdehyde;
one-carbon compound
allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1978201124.1low012310
glycinealpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid
EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
1969201334.6low01011210
glyceraldehydealdotriosefundamental metabolite1987198737.0low010000
glycerolalditol;
triol
algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
1969202233.9low2113113
glyoxylic acid2-oxo monocarboxylic acid;
aldehydic acid
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
201920195.0low000010
hydrogen carbonatecarbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1960201245.3low1536956640
histaminearalkylamino compound;
imidazoles
human metabolite;
mouse metabolite;
neurotransmitter
1954202243.8low19016811
hydrogenelemental hydrogen;
elemental molecule;
gas molecular entity
antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
1969200335.8low121100
iodinediatomic iodinenutrient1976200832.0low010100
iodinediatomic iodinenutrient1972200840.5low030100
dihydroxyphenylalaninehydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative
human metabolite1974198345.5low020000
thioctic aciddithiolanes;
heterocyclic fatty acid;
thia fatty acid
fundamental metabolite;
geroprotector
2005200519.0low000100
methanolalkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound
amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
1974197947.5low020000
inositolcyclitol;
hexol
1967199639.2low071000
melatoninacetamides;
tryptamines
anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
1994201418.5low103920
nickelmetal allergen;
nickel group element atom
epitope;
micronutrient
2002200222.0low000100
niacinamidepyridine alkaloid;
pyridinecarboxamide;
vitamin B3
anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
2002200222.0low000100
nitritesmonovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
human metabolite1968197154.5low020000
4-aminobenzoic acidaminobenzoic acid;
aromatic amino-acid zwitterion
allergen;
Escherichia coli metabolite;
plant metabolite
1977199840.4low3233000
phosphorylcholinephosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
1995200722.7low001200
1-propanolpropan-1-ols;
short-chain primary fatty alcohol
metabolite;
protic solvent
1979197945.0low010000
propionic acidsaturated fatty acid;
short-chain fatty acid
antifungal drug1983199336.0low011000
putrescinealkane-alpha,omega-diamineantioxidant;
fundamental metabolite
1988199333.2low023000
pyruvic acid2-oxo monocarboxylic acidcofactor;
fundamental metabolite
1988202119.5low010001
sarcosineN-alkylglycine zwitterion;
N-alkylglycine;
N-methyl-amino acid;
N-methylglycines
Escherichia coli metabolite;
glycine receptor agonist;
glycine transporter 1 inhibitor;
human metabolite;
mouse metabolite
1974197450.0low010000
spermidinepolyazaalkane;
triamine
autophagy inducer;
fundamental metabolite;
geroprotector
1988199333.8low022000
sperminepolyazaalkane;
tetramine
antioxidant;
fundamental metabolite;
immunosuppressive agent
1988199433.7low021000
succinic acidalpha,omega-dicarboxylic acid;
C4-dicarboxylic acid
anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent
202020204.0low000010
sulfuric acidsulfur oxoacidcatalyst1986198638.0low010000
taurineamino sulfonic acid;
zwitterion
antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
1969201934.5low041120
thiamineprimary alcohol;
vitamin B1
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2003200321.0low000100
uracilpyrimidine nucleobase;
pyrimidone
allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
1992199331.7low003000
uric aciduric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
1980202218.2low111002
ureaisourea;
monocarboxylic acid amide;
one-carbon compound
Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1973202040.6low060010
2-amino-5-phosphonovaleratenon-proteinogenic alpha-amino acidNMDA receptor antagonist1992201223.2low003110
2-amino-5-phosphonovaleratenon-proteinogenic alpha-amino acidNMDA receptor antagonist1992200726.0low003100
8-hydroxy-2-(di-n-propylamino)tetralinphenols;
tertiary amino compound;
tetralins
serotonergic antagonist1992200328.2low008100
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acidnon-proteinogenic alpha-amino acid1997200025.5low002000
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid1993200027.5low002000
4-iodo-2,5-dimethoxyphenylisopropylamineamphetamines;
dimethoxybenzene;
organoiodine compound
1996199628.0low001000
ibotenic acidnon-proteinogenic alpha-amino acidneurotoxin1985200132.5low032100
gallopamilbenzenes;
organic amino compound
1985198539.0low010000
sk&f-38393benzazepine;
catechols;
secondary amino compound
1989199632.0low013000
1-(3-chlorophenyl)piperazinemonochlorobenzenes;
N-arylpiperazine
drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
1998200921.0low002200
1-anilino-8-naphthalenesulfonateaminonaphthalene;
naphthalenesulfonic acid
fluorescent probe1960202241.5low26240543571
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinemethylpyridines;
phenylpyridine;
tetrahydropyridine
neurotoxin1986202228.3low023001
1-methylimidazoleimidazoles1982198242.0low010000
2,4-dinitrophenoldinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
1992199232.0low001000
2-methyl-5-httryptaminesserotonergic agonist2001200620.5low000200
2-aminoethoxydiphenyl borateorganoboron compound;
primary amino compound
calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener
2002201416.4low000410
n-methyl-3,4-methylenedioxyamphetamineamphetamines;
benzodioxoles
neurotoxin1994199430.0low001000
phaclofenorganophosphate oxoanion;
zwitterion
1993199530.0low003000
3-hydroxybenzylhydrazinephenols1983198341.0low010000
3-methoxytyraminemonomethoxybenzene;
phenols;
phenylethylamine;
primary amino compound
biomarker;
human blood serum metabolite;
human urinary metabolite
1989198935.0low010000
4-(2-aminoethyl)benzenesulfonylfluoride2002200222.0low000100
4-aminobenzamidine1984198440.0low010000
4-aminopyridineaminopyridine;
aromatic amine
avicide;
orphan drug;
potassium channel blocker
1993200724.0low001100
4-diphenylacetoxy-1,1-dimethylpiperidiniumquaternary ammonium ioncholinergic antagonist;
muscarinic antagonist
1991200924.8low002200
homovanillic acidguaiacols;
monocarboxylic acid
human metabolite;
mouse metabolite
1983200131.3low3412100
phenytoinimidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
1997199727.0low001000
ethylisopropylamiloridearomatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound
anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker
1998199826.0low001000
5-carboxamidotryptaminetryptamines1993199331.0low001000
hydroxyindoleacetic acidindole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
1990200030.2low206000
7-nitroindazole1997199727.0low001000
8-cyclopentyl-1,3-dimethylxanthineoxopurine2005200519.0low000200
aa 8611,4-benzoquinones;
acetylenic compound;
primary alcohol
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
1988198836.0low010000
acetaminophenacetamides;
phenols
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
1997202213.4low601531
acetazolamidemonocarboxylic acid amide;
sulfonamide;
thiadiazoles
anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
1967196956.0low030000
tyrphostin a23catechols2001200123.0low000100
alaproclatealpha-amino acid ester1989199532.0low011000
alendronate1,1-bis(phosphonic acid);
primary amino compound
bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
201620168.0low000010
alosetronimidazoles;
pyridoindole
antiemetic;
gastrointestinal drug;
serotonergic antagonist
2007200717.0low000100
aluminum fluoridealuminium coordination entity1995199827.5low002000
am 251amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles
antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist
2007201511.8low000230
diatrizoic acidacetamides;
benzoic acids;
organoiodine compound
environmental contaminant;
radioopaque medium;
xenobiotic
1974197450.0low010000
pimagedineguanidines;
one-carbon compound
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
1996200423.0low001200
theophyllinedimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
1968200547.1low2363200
amitriptylinecarbotricyclic compound;
tertiary amine
adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
1982199436.0low011000
antipyrinepyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
1982198242.0low010000
aspirinbenzoic acids;
phenyl acetates;
salicylates
anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
1993199529.6low005000
baclofenamino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound
central nervous system depressant;
GABA agonist;
muscle relaxant
1986201328.1low018010
bay-k-8644(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
1990200127.2low004100
benoxathian1998200522.5low001100
benzocainebenzoate ester;
substituted aniline
allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
1971200928.2low110300
bethanecholcarbamate ester;
quaternary ammonium ion
muscarinic agonist1982201230.8low01011410
bisindolylmaleimide i1999201220.5low004510
brotizolamorganic molecular entity1993199331.0low001000
bumetanideamino acid;
benzoic acids;
sulfonamide
diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
2008200816.0low000100
buspironeazaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines
anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
1999199925.0low001000
busulfanmethanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
1975197549.0low010000
caffeinepurine alkaloid;
trimethylxanthine
adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
1968200832.8low0712500
verapamilaromatic ether;
nitrile;
polyether;
tertiary amino compound
1977199835.2low054000
calmidazoliumimidazolium ionapoptosis inducer;
calmodulin antagonist
1998199826.0low001000
camostatbenzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide
anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
1982201629.5high22337840
camphor, (+-)-isomerbornane monoterpenoid;
cyclic monoterpene ketone
plant metabolite1994199430.0low001000
carmustineN-nitrosoureas;
organochlorine compound
alkylating agent;
antineoplastic agent
1993199331.0low001000
carbonyl cyanide m-chlorophenyl hydrazonehydrazone;
monochlorobenzenes;
nitrile
antibacterial agent;
geroprotector;
ionophore
1976200633.6low041200
chelerythrinebenzophenanthridine alkaloid;
organic cation
antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
1997201417.7low001110
chloral hydratealdehyde hydrate;
ethanediol;
organochlorine compound
general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
1986198638.0low010000
chlordiazepoxidebenzodiazepine1985199137.0low021000
chloroquineaminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
1988202027.8low013010
chlorpheniraminemonochlorobenzenes;
pyridines;
tertiary amino compound
anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
1990199034.0low001000
chlorpromazineorganochlorine compound;
phenothiazines;
tertiary amine
anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
1982198838.6low080000
cimetidinealiphatic sulfide;
guanidines;
imidazoles;
nitrile
adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
1978199838.2low174000
cisapridebenzamides1986199631.3low439000
citalopram2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
1987199929.7low112000
clofibratearomatic ether;
ethyl ester;
monochlorobenzenes
anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
1971197153.0low010000
clomipraminedibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
1994199430.0low001000
clonazepam1,4-benzodiazepinone;
monochlorobenzenes
anticonvulsant;
anxiolytic drug;
GABA modulator
1983199434.0low012000
clonidineclonidine;
imidazoline
1979199935.9low044000
phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide1999199925.0low001000
cycloleucinenon-proteinogenic alpha-amino acidEC 2.5.1.6 (methionine adenosyltransferase) inhibitor1983199734.0low011000
cyclo(leucylglycine)1983198341.0low010000
cyproheptadinepiperidines;
tertiary amine
anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
1982198540.5low020000
decanoic acidmedium-chain fatty acid;
straight-chain saturated fatty acid
algal metabolite;
anti-inflammatory agent;
antibacterial agent;
human metabolite;
plant metabolite;
volatile oil component
2000201318.8low201210
desipraminedibenzoazepine;
secondary amino compound
adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
1986199036.3low021000
amphetamineprimary amine1979201428.0low0410330
eflornithinealpha-amino acid;
fluoroamino acid
trypanocidal drug1985199435.5low051000
r 59022diarylmethane1990199034.0low001000
diazepam1,4-benzodiazepinone;
organochlorine compound
anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
1976200936.1low12011300
diazinonorganic thiophosphate;
pyrimidines
acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
nematicide;
xenobiotic
1987198737.0low010000
diazoxidebenzothiadiazine;
organochlorine compound;
sulfone
antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
1969197850.4low070000
dibucainearomatic ether;
monocarboxylic acid amide;
tertiary amino compound
topical anaesthetic1974197450.0low010000
diclofenacamino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound
antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
2007200717.0low000100
diethyl pyrocarbonateacyclic carboxylic anhydride1978197846.0low010000
pentetic acidpentacarboxylic acidcopper chelator1990201221.3low002310
dimapritimidothiocarbamic ester1980199039.0low011000
dimethadioneoxazolidinone1975197847.8low040000
diphenhydramineether;
tertiary amino compound
anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
1967202036.7low020010
diphenyleneiodoniumorganic cation202020204.0low000010
disopyramidemonocarboxylic acid amide;
pyridines;
tertiary amino compound
anti-arrhythmia drug1994199629.3low003000
disulfiramorganic disulfide;
organosulfur acaricide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
1993199331.0low001000
disulfotonorganic thiophosphate;
organothiophosphate insecticide
acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
1984198440.0low010000
racemetirosine1981199237.6low032000
thiorphanN-acyl-amino acid1992199232.0low001000
domperidonebenzimidazoles;
heteroarylpiperidine
antiemetic;
dopaminergic antagonist
1984200629.0low110100
dsp 41998199826.0low001000
edrophoniumphenols;
quaternary ammonium ion
antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
1993199331.0low001000
epinastinebenzazepine;
guanidines
anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug
2014201410.0low000010
erythrosine1981200733.1low062200
ethacrynic acidaromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid
EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
1972200238.7low020100
etherether;
volatile organic compound
inhalation anaesthetic;
non-polar solvent;
refrigerant
1996199628.0low001000
carbonyl cyanide p-trifluoromethoxyphenylhydrazonearomatic ether;
hydrazone;
nitrile;
organofluorine compound
ATP synthase inhibitor;
geroprotector;
ionophore
2001200719.3low000300
fenfluramine(trifluoromethyl)benzenes;
secondary amino compound
appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
1982200330.0low0311200
fenoldopambenzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
201620168.0low000010
fentanylanilide;
monocarboxylic acid amide;
piperidines
adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
1998199826.0low001000
flufenamic acidaromatic amino acid;
organofluorine compound
antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
202020204.0low000010
flumazenilethyl ester;
imidazobenzodiazepine;
organofluorine compound
antidote to benzodiazepine poisoning;
GABA antagonist
1982199934.9low043000
flunitrazepam1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes
anxiolytic drug;
GABAA receptor agonist;
sedative
1990199631.0low002000
fluorouracilnucleobase analogue;
organofluorine compound
antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
1978198443.0low120000
fluoxetine(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
1990201717.0low001120
flurazepam1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound
anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
1985199436.2low041000
furosemidechlorobenzoic acid;
furans;
sulfonamide
environmental contaminant;
loop diuretic;
xenobiotic
1968199940.8low032000
gabexatebenzoate ester1982201629.8medium22637840
guanidinoethylmercaptosuccinic acid1995199529.0low001000
glyburidemonochlorobenzenes;
N-sulfonylurea
anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
1974199538.5low033000
go 6976indolocarbazole;
organic heterohexacyclic compound
EC 2.7.11.13 (protein kinase C) inhibitor2011201113.0low000010
guaifenesinmethoxybenzenes1976201335.2low032010
guanethidineazocanes;
guanidines
adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
1989200528.8low012100
guanidinecarboxamidine;
guanidines;
one-carbon compound
1999199925.0low001000
1-(5-isoquinolinesulfonyl)-2-methylpiperazineisoquinolines;
N-sulfonylpiperazine
EC 2.7.11.13 (protein kinase C) inhibitor1990201926.6low007010
haloperidolaromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol
antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
1981201534.4low12321210
halothanehaloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound
inhalation anaesthetic1974198841.3low060000
harmalineharmala alkaloidoneirogen1988198836.0low010000
hexamethoniumquaternary ammonium salt1987200430.2low0414200
hexobarbitalbarbiturates1980198044.0low010000
alpha-methylhistaminearalkylamino compound;
imidazoles
animal metabolite;
H3-receptor agonist
2001200123.0low000100
hydralazineazaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines
antihypertensive agent;
vasodilator agent
2006200618.0low000100
lidocainebenzenes;
monocarboxylic acid amide;
tertiary amino compound
anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
1969200438.1low163200
alverinetertiary amineantispasmodic drug1999199925.0low001000
ifenprodilpiperidines2000200024.0low001000
imipraminedibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
1993200826.0low002100
indomethacinaromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole
analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
1974201231.2low089510
iodipamidebenzoic acids;
organoiodine compound;
secondary carboxamide
radioopaque medium1964198254.0low030000
1-methyl-3-isobutylxanthine3-isobutyl-1-methylxanthine1984200031.4low0415000
isofluraneorganofluorine compoundinhalation anaesthetic1988198836.0low010000
isoniazidcarbohydrazideantitubercular agent;
drug allergen
1981198143.0low010000
isoniazidcarbohydrazideantitubercular agent;
drug allergen
1980198143.5low020000
2-propanolsecondary alcohol;
secondary fatty alcohol
protic solvent1985199235.5low011000
isoproterenolcatechols;
secondary alcohol;
secondary amino compound
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
1964201543.8low0327010
itopridebenzamides2006200618.0low100100
ketaminecyclohexanones;
monochlorobenzenes;
secondary amino compound
analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
1987200130.5low021100
ketanserinaromatic ketone;
organofluorine compound;
piperidines;
quinazolines
alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
1994200126.5low001100
ketotifencyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound
anti-asthmatic drug;
H1-receptor antagonist
1998200621.7low001200
kynurenic acidmonohydroxyquinoline;
quinolinemonocarboxylic acid
G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
1992200723.4low003200
lamotrigine1,2,4-triazines;
dichlorobenzene;
primary arylamine
anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
2001200123.0low000100
lauric acidmedium-chain fatty acid;
straight-chain saturated fatty acid
algal metabolite;
antibacterial agent;
plant metabolite
2000202214.9low701521
lavendustin aaromatic amine1996199628.0low001000
loperamidemonocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol
anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
1984200530.0low212100
lorazepambenzodiazepine1986198638.0low010000
lorglumidebenzamides;
dicarboxylic acid monoamide;
dichlorobenzene;
glutamic acid derivative
1986201929.2high029612050
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-onechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
1998200721.0low001200
6-anilino-5,8-quinolinedioneaminoquinoline;
aromatic amine;
p-quinones;
quinolone
antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor
1997200125.0low001100
maprotilineanthracenes1993199331.0low001000
mazindolorganic molecular entity1991199133.0low001000
mecamylamineprimary aliphatic amine1986198638.0low010000
mechlorethaminenitrogen mustard;
organochlorine compound
alkylating agent1992199331.5low002000
medazepamorganic molecular entity1985198539.0low010000
meperidineethyl ester;
piperidinecarboxylate ester;
tertiary amino compound
antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
1963197853.5low040000
metforminguanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
200820179.8low200130
methadonebenzenes;
diarylmethane;
ketone;
tertiary amino compound
1963199047.5low011000
methiothepinaryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound
antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
1994199430.0low001000
nocodazolearomatic ketone;
benzimidazoles;
carbamate ester;
thiophenes
antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
2000200024.0low001000
methylphenidatebeta-amino acid ester;
methyl ester;
piperidines
201520159.0low000010
metoclopramidebenzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound
antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
1974200933.2low142200
muscimolalkaloid;
isoxazoles;
primary amino compound
fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
1982200732.3low041200
n-(6-aminohexyl)-1-naphthalenesulfonamidenaphthalenes;
sulfonic acid derivative
2000200024.0low001000
ethylmaleimidemaleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
1994199529.7low003000
fg 7142beta-carbolines1990199532.0low003000
fenamic acidaminobenzoic acid;
secondary amino compound
membrane transport modulator2000200024.0low001000
nafamostatbenzoic acids;
guanidines
2002200222.0low000100
neostigminequaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
1966199150.0low0221000
nicardipinebenzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
1990200327.2low004100
nifedipineC-nitro compound;
dihydropyridine;
methyl ester
calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
1986200727.2low037700
nimodipine2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester
antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
1999199925.0low001000
nitrendipineC-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester
antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
1987198737.0low010000
nitroglycerinnitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
1970202032.7low023110
nomifensineisoquinolinesdopamine uptake inhibitor1993199430.5low002000
nortriptylineorganic tricyclic compound;
secondary amine
adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
1994199430.0low001000
octopaminephenylethanolamines;
tyramines
neurotransmitter1974201431.3low011010
omeprazolearomatic ether;
benzimidazoles;
pyridines;
sulfoxide
1988201327.5low118110
ondansetroncarbazoles1992200623.3low105700
oxethazaineamino acid amide1982198242.0low010000
oxidopaminebenzenetriol;
catecholamine;
primary amino compound
drug metabolite;
human metabolite;
neurotoxin
1982201530.4low059210
oxotremorineN-alkylpyrrolidine1983198341.0low010000
oxymetazolinecarboxamidine;
imidazolines;
phenols
alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
1974197450.0low010000
aminosalicylic acidaminobenzoic acid;
phenols
antitubercular agent1990199034.0low002000
quinone1,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
1996199628.0low001000
fencloninephenylalanine derivative1990200725.0low002100
papaverinebenzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines
antispasmodic drug;
vasodilator agent
1966198947.5low080000
pargylinearomatic amine1980199739.0low031000
pd 98059aromatic amine;
monomethoxyflavone
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
2001200422.2low000600
pentobarbitalbarbituratesGABAA receptor agonist1969199841.9low093000
phenobarbitalbarbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
1975200334.3low011100
phenolsulfonphthalein2,1-benzoxathiole;
arenesulfonate ester;
phenols;
sultone
acid-base indicator;
diagnostic agent;
two-colour indicator
1975202230.8low021001
phenoxybenzaminearomatic amine1966198050.5low0110000
phentermineprimary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
201520159.0low100010
4-phenylbutyric acidmonocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
2013201311.0low000010
oxophenylarsinearsine oxidesantineoplastic agent;
apoptosis inducer;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
1990199034.0low001000
phenyl biguanideguanidinescentral nervous system drug1984200821.9low010600
phenylmethylsulfonyl fluorideacyl fluorideserine proteinase inhibitor1989199532.0low011000
phloretindihydrochalconesantineoplastic agent;
plant metabolite
1974201927.5low010010
pioglitazonearomatic ether;
pyridines;
thiazolidinediones
antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
2006200618.0low000100
pirenzepinepyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
1988200930.8low3313100
potassium chlorideinorganic chloride;
inorganic potassium salt;
potassium salt
fertilizer1975201425.9low1511930
4-aminobenzoic acidaminobenzoate;
aromatic amino-acid anion
Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
1977201238.6low2101010
ag 1879aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine
beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
201520159.0low000010
prazosinaromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines
alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
1992199630.7low003000
probenecidbenzoic acids;
sulfonamide
uricosuric drug1985198539.0low010000
procainamidebenzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
1967196757.0low010000
procainebenzoate ester;
substituted aniline;
tertiary amino compound
central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
1974199041.3low021000
proglumidebenzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate
anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite
1981202330.8high471252164083
propanthelinexanthenes1968198248.8low060000
propentofyllineoxopurine1985198539.0low010000
propidiumphenanthridines;
quaternary ammonium ion
fluorochrome;
intercalator
2003200321.0low000100
propofolphenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
1992199232.0low001000
propranololnaphthalenes;
propanolamine;
secondary amine
anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
1970200342.9low1246200
pyrilaminearomatic ether;
ethylenediamine derivative
H1-receptor antagonist1979200137.3low020100
quipazinepiperazines;
pyridines
1982198242.0low010000
opc 12759secondary carboxamide2004200420.0low000100
risperidone1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine
alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
201520159.0low000010
ritanserinorganofluorine compound;
piperidines;
thiazolopyrimidine
antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
1994199828.0low002000
rizatriptantryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
201520159.0low000010
ro 31-8220imidothiocarbamic ester;
indoles;
maleimides
EC 2.7.11.13 (protein kinase C) inhibitor2007200717.0low000100
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinonemethoxybenzenes1992199232.0low001000
saccharin1,2-benzisothiazole;
N-sulfonylcarboxamide
environmental contaminant;
sweetening agent;
xenobiotic
1974201226.8low021120
sb 202190imidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
2004200420.0low000100
sibutramineorganochlorine compound;
tertiary amino compound
anti-obesity agent;
serotonin uptake inhibitor
2008200816.0low000100
sk&f 975412000200024.0low001000
sodium fluoridefluoride saltmutagen1979200433.2low035100
ipodate1964198251.0low030000
sotalolethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide
anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
1992199232.0low001000
spiperonearomatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound
alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
1981198540.7low070000
stearic acidlong-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid
algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite
2000200024.0low001000
sulfanilamidesubstituted aniline;
sulfonamide antibiotic;
sulfonamide
antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
1961196163.0low010000
sulfobromophthalein2-benzofurans;
organobromine compound;
organosulfonic acid;
phenols
dye1970197751.0low030000
sulpiridebenzamides;
N-alkylpyrrolidine;
sulfonamide
antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
1980199835.0low176000
tegafurorganohalogen compound;
pyrimidines
1992199331.7low003000
telenzepinebenzodiazepine1996200923.5low103100
terbutalinephenylethanolamines;
resorcinols
anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
1976198741.8low050000
tetracainebenzoate ester;
tertiary amino compound
local anaesthetic1972197750.0low060000
tetraethylammoniumquaternary ammonium ion1993200923.0low001100
kryptonmonoatomic krypton;
noble gas atom;
p-block element atom
1973197450.5low020000
tetraisopropylpyrophosphamidephosphoramide1989199034.5low011000
theobrominedimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
1969197253.5low020000
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoatetrihydroxybenzoic acid1983198341.0low010000
tolazolineimidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
1982198242.0low010000
tolbutamideN-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
1969198947.5low0150000
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamineN-substituted diamine;
pyridines;
tertiary amino compound
apoptosis inducer;
chelator;
copper chelator
2003200321.0low000100
tranexamic acidamino acid2011201113.0low000010
triazolamtriazolobenzodiazepinesedative1992199232.0low001000
trifluoperazineN-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines
antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
1983198540.0low020000
trimethadioneoxazolidinoneanticonvulsant;
geroprotector
1973197749.0low040000
trimipraminedibenzoazepine;
tertiary amino compound
antidepressant;
environmental contaminant;
xenobiotic
1987198737.0low010000
tripelennaminearomatic amine1974197450.0low010000
troglitazonechromanes;
thiazolidinone
anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
2000200223.0low001100
urethanecarbamate esterfungal metabolite;
mutagen
1969199840.5low011000
w 71998200025.0low003000
pirinixic acidaryl sulfide;
organochlorine compound;
pyrimidines
1997199727.0low001000
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine2002200222.0low000100
xylazine1,3-thiazine;
methylbenzene;
secondary amino compound
alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
1976199936.5low011000
zonisamide1,2-benzoxazoles;
sulfonamide
anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
2008200816.0low000100
mitomycinmitomycinalkylating agent;
antineoplastic agent
1984198440.0low110000
oxyphenoniumacylcholine1975197549.0low010000
corticosterone11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone
human metabolite;
mouse metabolite
1979201627.6low086830
prednisolone11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
1975197549.0low010000
lysergic acid diethylamideergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound
dopamine agonist;
hallucinogen;
serotonergic agonist
1986198638.0low010000
reserpinealkaloid ester;
methyl ester;
yohimban alkaloid
adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
1972198445.3low070000
phentolamineimidazoles;
phenols;
substituted aniline;
tertiary amino compound
alpha-adrenergic antagonist;
vasodilator agent
1971201438.4low0177110
sorbitolglucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
1960199847.1low095000
alloxanpyrimidonehyperglycemic agent;
metabolite
1968198648.3low030000
thymidinepyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
1973200830.4low0115200
thyroxine2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine
antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
1979201525.2low012110
dibenzylchlorethamine1985198638.5low020000
dextroamphetamine1-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
1979199038.0low031000
carbacholammonium salt;
carbamate ester
cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
1966201636.6low0142661850
aldosterone11beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde
human metabolite;
mouse metabolite
1980202024.7low120310
pentolinium tartratetartrate saltantihypertensive agent1970197054.0low020000
penicillaminenon-proteinogenic alpha-amino acid;
penicillamine
antirheumatic drug;
chelator;
copper chelator;
drug allergen
1985198937.0low020000
prednisone11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
1975197549.0low010000
estrone17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols
antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
2007201812.7low000210
pilocarpinepilocarpineantiglaucoma drug1963202341.5low0261211
dimethylphenylpiperazinium iodideN-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt
nicotinic acetylcholine receptor agonist1977198742.0low020000
pentylenetetrazoleorganic heterobicyclic compound;
organonitrogen heterocyclic compound
1980201529.3low023010
triiodothyronine2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine
human metabolite;
mouse metabolite;
thyroid hormone
1972200835.7low020100
isoflurophatedialkyl phosphate1968199640.6low041000
biguanidesguanidines1984200821.9low010600
carbon tetrachloridechlorocarbon;
chloromethanes
hepatotoxic agent;
refrigerant
1993199928.0low002000
alaninealanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid
EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
1970200838.8low0102300
serineL-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1974200628.7low024300
chloramphenicolC-nitro compound;
carboxamide;
diol;
organochlorine compound
antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
1974197649.0low020000
aspartic acidaspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid
Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
1971200832.2low1914500
glutamineamino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
1973202135.9low47017101
lysineaspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid
algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
1968202324.0low045641
cyanidespseudohalide anionEC 1.9.3.1 (cytochrome c oxidase) inhibitor1967196757.0low010000
physostigminecarbamate ester;
indole alkaloid
antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
1967198945.3low060000
sucroseglycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
1973202224.1low710156103
ethinyl estradiol17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound
xenoestrogen2013201311.0low000010
tubocurarinebisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
1971197153.0low010000
apomorphineaporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
1974200136.5low02211200
aminopyrinepyrazolone;
tertiary amino compound
antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
1977200034.9low034000
tetrabenazinebenzoquinolizine;
cyclic ketone;
tertiary amino compound
1983198341.0low010000
adenosine diphosphateadenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate
fundamental metabolite;
human metabolite
1989201024.5low010100
uridineuridinesdrug metabolite;
fundamental metabolite;
human metabolite
1986198638.0low010000
bromodeoxyuridinepyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
1994200824.5low003100
galactoseD-galactose;
galactopyranose
Escherichia coli metabolite;
mouse metabolite
1972198048.0low030000
carbostyrilmonohydroxyquinoline;
quinolone
bacterial xenobiotic metabolite2004200420.0low000100
phenylephrinephenols;
phenylethanolamines;
secondary amino compound
alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
1974200732.2low054400
levodopaamino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid
allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
1980199535.8low124000
edetic acidethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid
anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
1972200140.4low0111100
tributyrinbutyrate ester;
triglyceride
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug;
protective agent
201520159.0low100010
tyrosineamino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine
EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
1969202229.2low119211432
cysteamineamine;
thiol
geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
1990199929.5low002000
methoxamineamphetaminesalpha-adrenergic agonist;
antihypotensive agent
1973199639.5low011000
adenosine monophosphateadenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate
adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
202220222.0low000001
methylene blueorganic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
1997199727.0low001000
leucineamino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
1964202340.7low4314331
methacholine chloridequaternary ammonium salt1981199537.8low041000
dimethylnitrosaminenitrosaminegeroprotector;
mutagen
1989198935.0low010000
uridine triphosphatepyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate
Escherichia coli metabolite;
mouse metabolite
1991199133.0low001000
lactoselactose1970200633.7low230400
methionineaspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid
antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
1969202043.4low0264110
phenylalanineamino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid
algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
1966202336.5low53924641
desoxycorticosterone20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone
human metabolite;
mouse metabolite
1966200135.7low011100
colchicinealkaloid;
colchicine
anti-inflammatory agent;
gout suppressant;
mutagen
1972200334.5low098200
cycloheximideantibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol
anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
1971201039.3low0125200
egtazic aciddiether;
tertiary amino compound;
tetracarboxylic acid
chelator1977201928.6low0911730
dimethylformamideformamides;
volatile organic compound
geroprotector;
hepatotoxic agent;
polar aprotic solvent
1998199826.0low001000
17-alpha-hydroxyprogesterone17alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone
human metabolite;
metabolite;
mouse metabolite;
progestin
2005201315.0low000110
chlorisondamineisoindoles1992199232.0low001000
ampicillinbeta-lactam antibiotic;
penicillin allergen;
penicillin
antibacterial drug1964196460.0low010000
mannitolmannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
1975199741.5low142000
cytarabinebeta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside
antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
1992200028.0low002000
dithionitrobenzoic acidnitrobenzoic acid;
organic disulfide
indicator1987198737.0low010000
ornithinenon-proteinogenic L-alpha-amino acid;
ornithine
algal metabolite;
hepatoprotective agent;
mouse metabolite
1985198539.0low020000
asparagineamino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
1999200323.8low003100
histidineamino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid
algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
1969200835.1low033200
medroxyprogesterone acetate20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester
adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
1992199232.0low001000
valineL-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine
algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
1968201926.9low130040
threonineamino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine
algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
1973201331.0low010010
tryptophanerythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan
antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
1968202233.1low83114672
isoleucineaspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
1994201617.7low101110
argininearginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid
biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
1968202234.2low02119641
acetonitrilealiphatic nitrile;
volatile organic compound
EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
1998199826.0low001000
trifluoroacetic acidfluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent
1993199828.5low002000
phencyclidinebenzenes;
piperidines
anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
1990199432.2low004000
tromethamineprimary amino compound;
triol
buffer1972197252.0low010000
bisphenol abisphenolendocrine disruptor;
environmental contaminant;
xenobiotic;
xenoestrogen
2014201410.0low000010
dehydrocholic acid12-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid
gastrointestinal drug1964197553.0low050000
taurocholic acidamino sulfonic acid;
bile acid taurine conjugate
human metabolite1972201536.1low01710510
methylprednisolone6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
1996199628.0low001000
rotenoneorganic heteropentacyclic compound;
rotenones
antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
201520159.0low000010
isosorbide dinitrateglucitol derivative;
nitrate ester
nitric oxide donor;
vasodilator agent
1985198539.0low010000
xylitol202120213.0low100001
n-vinyl-2-pyrrolidinonepyrrolidin-2-ones1984200728.5low010100
1-naphtholnaphtholgenotoxin;
human xenobiotic metabolite
1994199430.0low001000
quinoxalinesmancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
1992201617.6low002420
2-naphthylaminenaphthylaminecarcinogenic agent2008200816.0low000100
3,3'-diaminobenzidinebiphenyls;
substituted aniline
histological dye1987198737.0low010000
tolonium chloride1993199331.0low001000
xanthenesxanthene1968200830.2low012200
propylparabenbenzoate ester;
paraben;
phenols
antifungal agent;
antimicrobial agent
1994199430.0low001000
butylparabenorganic molecular entity1994199430.0low001000
4-butyrolactonebutan-4-olidemetabolite;
neurotoxin
1995199529.0low001000
pyrrolidonecarboxylic acid5-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid
algal metabolite1980201031.6low042100
quinuclidinesquinuclidines;
saturated organic heterobicyclic parent
1977197747.0low010000
betazoleprimary amino compound;
pyrazoles
diagnostic agent;
gastrointestinal drug;
histamine agonist
1980198044.0low010000
epichlorohydrinepoxide;
organochlorine compound
2008200816.0low000100
acroleinenalherbicide;
human xenobiotic metabolite;
toxin
1998201318.5low001010
cyclohexanolcyclohexanols;
secondary alcohol
solvent2001201814.5low000110
n-pentanoic acidshort-chain fatty acid;
straight-chain saturated fatty acid
plant metabolite2013201311.0low000010
pyrrolespyrrole;
secondary amine
1991200327.0low001100
thiophenesmancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound
non-polar solvent1991199930.8low006000
ergotaminepeptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
1967198748.0low030000
phenforminbiguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
1973197351.0low010000
framycetinaminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
1974197450.0low010000
diatrizoate megluminemonocarboxylic acid anionradioopaque medium1979197945.0low010000
megluminehexosamine;
secondary amino compound
1990201427.4low0056920
2-naphtholnaphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
1994200126.5low001100
hexanoic acidmedium-chain fatty acid;
straight-chain saturated fatty acid
human metabolite;
plant metabolite
1993199331.0low001000
iminodiacetic acidamino dicarboxylic acid;
glycine derivative;
non-proteinogenic alpha-amino acid
chelator1984201520.0low010120
20-alpha-dihydroprogesterone20-hydroxypregn-4-en-3-onehuman metabolite;
mouse metabolite
2005201315.0low000110
yohimbinemethyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
1990199928.8low006000
3-o-methylglucoseD-aldohexose derivative1982199635.0low011000
ditiocarbdithiocarbamic acidschelator;
copper chelator
1984199833.0low011000
1,2-dihydroxybenzene-3,5-disulfonic acid disodium saltorganic molecular entity202020204.0low000010
quinazolinesazaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
1985201624.8low027610
indazolesindazole1997199727.0low001000
benzoxazoles1,3-benzoxazoles;
mancude organic heterobicyclic parent
202020204.0low000010
adamantaneadamantanes;
polycyclic alkane
1993201420.8low002110
cyclopentanecycloalkane;
cyclopentanes;
volatile organic compound
non-polar solvent1970199143.5low011000
isoxazolesisoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1992200824.0low001100
oxazoles1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1973200438.9low051200
thiazoles1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1986202022.5low1112840
pyrazinesdiazine;
pyrazines
Daphnia magna metabolite1991199829.5low002000
nitroblue tetrazoliumorganic cation1983198341.0low010000
calcium gluconatecalcium saltnutraceutical2003200321.0low000100
muscarinemonosaccharide1994201121.5low001010
hydrazineazane;
hydrazines
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor1974198346.0low030000
aminophyllinemixturebronchodilator agent;
cardiotonic drug
1966200347.1low070100
perfluorooctanoic acidfluoroalkanoic acidcarcinogenic agent;
endocrine disruptor;
environmental contaminant;
surfactant;
xenobiotic
2000200223.0low001100
methysergideergoline alkaloid1968199046.3low051000
citrullineamino acid zwitterion;
citrulline
Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite
1993200227.3low002100
lithocholic acidbile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid
geroprotector;
human metabolite;
mouse metabolite
1973198148.8low040000
thiazolidine-4-carboxylic acidalpha-amino acid zwitterion;
non-proteinogenic alpha-amino acid;
sulfur-containing amino acid;
thiazolidinemonocarboxylic acid
antidote;
antioxidant;
hepatoprotective agent
1995199529.0low001000
n-pentyl nitritenitrite estersvasodilator agent1963202040.7low040020
chenodeoxycholic acidbile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid
human metabolite;
mouse metabolite
1973201341.6low2141010
glycocholic acidbile acid glycine conjugatehuman metabolite1978198742.6low050000
phosphoadenosine phosphosulfateacyl sulfate;
adenosine bisphosphate;
purine ribonucleoside bisphosphate
Escherichia coli metabolite;
mouse metabolite
1990199133.5low002000
bicucullinebenzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines
agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
1980200629.4low047300
kainic aciddicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid
antinematodal drug;
excitatory amino acid agonist
1981202129.0low0107231
phenylpropanolamineamphetamines;
phenethylamine alkaloid
plant metabolite1991199133.0low001000
alpha-aminopyridine1979197945.0low010000
thiazolidinesthiazolidine1995200026.5low002000
cyanogen bromide1974199539.5low011000
dihydroergotamineergot alkaloid;
semisynthetic derivative
dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
1978197846.0low010000
echothiophate iodideiodide salt;
quaternary ammonium salt
antiglaucoma drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
1989199034.5low011000
medroxyprogesterone17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone
contraceptive drug;
progestin;
synthetic oral contraceptive
1992199232.0low001000
dihydrotestosterone17beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid
androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
2008201611.7low000120
methoxyhydroxyphenylglycolmethoxybenzenes;
phenols
1994200027.0low102000
methamphetamineamphetamines;
secondary amine
central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
1982202025.3low036130
tricaprylinoctanoate ester;
triglyceride
anticonvulsant;
plant metabolite
1992199331.7low003000
dicyclohexylcarbodiimidecarbodiimideATP synthase inhibitor;
cross-linking reagent;
peptide coupling reagent
1986198638.0low010000
malondialdehydedialdehydebiomarker1994201619.0low001010
myristic acidlong-chain fatty acid;
straight-chain saturated fatty acid
algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
2000200024.0low001000
trinitrobenzenesulfonic acidarenesulfonic acid;
C-nitro compound
epitope;
explosive;
reagent
1998199826.0low001000
4-chloromercuribenzenesulfonatearenesulfonic acid;
arylmercury compound
1997199727.0low001000
diisopropylnitrosamine1983198341.0medium010000
acetylcysteineacetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid
antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
1991200126.7low002100
2,6-dichloro-4-nitrophenol1987198737.0low010000
erythromycincyclic ketone;
erythromycin
1990201224.0low103210
mannoheptuloseD-manno-heptulose1993199331.0low001000
hexafluoroacetoneketone;
perfluorinated compound
NMR chemical shift reference compound2002200222.0low000100
cytidine diphosphate cholinenucleotide-(amino alcohol)s;
phosphocholines
human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
1986198638.0low010000
rhodamine 6g1992199232.0low001000
allylglycine1998200124.5low003100
sodium hydroxidealkali metal hydroxide1981198143.0low010000
hydrofluoric acidhydrogen halide;
mononuclear parent hydride
NMR chemical shift reference compound1977197747.0low010000
glycyrrhizic acidenone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin
EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
1997199727.0low001000
selenomethionineselenoamino acid;
selenomethionines
plant metabolite1974198846.6low090000
[2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammoniumamino acid amide2011201113.0low000010
s,n,n'-tripropylthiocarbamatetertiary amine1983202217.6low131233
dronabinolbenzochromene;
diterpenoid;
phytocannabinoid;
polyketide
cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
201720177.0low000010
amiloridearomatic amine;
guanidines;
organochlorine compound;
pyrazines
diuretic;
sodium channel blocker
1973200134.2low032100
pimozidebenzimidazoles;
heteroarylpiperidine;
organofluorine compound
antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
1985199235.5low011000
fluorescein2-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye
fluorescent dye;
radioopaque medium
2002200222.0low000100
flupenthixolthioxanthenes1978197846.0low010000
fucosefucopyranose;
L-fucose
Escherichia coli metabolite;
mouse metabolite
1976197648.0low020000
ioglycamic acidamidobenzoic acid1975198245.5low020000
dicloxacillindichlorobenzene;
penicillin
antibacterial drug1980198044.0low010000
fluorescein-5-isothiocyanatefluorescein isothiocyanate1987201426.2low012010
dithiothreitol1,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol
chelator;
human metabolite;
reducing agent
1983199635.0low021000
denatonium benzoate2006201414.0low000110
norleucine2-aminohexanoic acid;
L-alpha-amino acid zwitterion;
non-proteinogenic L-alpha-amino acid
1978198144.5low020000
tocamphylcarboxylic ester1994199430.0medium001000
n-methylaspartateamino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound
neurotransmitter agent1992202224.5low0019331
xylamidine1989198935.0low010000
bipiperidyl mustard1987198737.0low010000
lanthanumf-block element atom;
lanthanoid atom;
scandium group element atom
1981200235.4low042100
lutetiumd-block element atom;
lanthanoid atom
201620168.0low000010
manganeseelemental manganese;
manganese group element atom
Escherichia coli metabolite;
micronutrient
1974199441.5low082000
palladiummetal allergen;
nickel group element atom;
platinum group metal atom
2001200123.0low000100
rheniummanganese group element atom2002200222.0low000100
technetiummanganese group element atom1975201539.1low0341030
cadmiumcadmium molecular entity;
zinc group element atom
2009200915.0low000100
gadoliniumf-block element atom;
lanthanoid atom
2000200918.7low001200
goldcopper group element atom;
elemental gold
1982198540.5low020000
magnesium sulfatemagnesium salt;
metal sulfate;
organic magnesium salt
anaesthetic;
analgesic;
anti-arrhythmia drug;
anticonvulsant;
calcium channel blocker;
cardiovascular drug;
fertilizer;
tocolytic agent
1960200049.3low0171000
mercuric chloridemercury coordination entitysensitiser2013201311.0low000010
galactosamineD-galactosamine;
primary amino compound
toxin1986198638.0low010000
phosphoric acid, trisodium saltsodium phosphate2014201410.0low000010
barium sulfatebarium salt;
inorganic barium salt;
metal sulfate
radioopaque medium1970198049.1low170000
tricalcium phosphatecalcium phosphate201920195.0low000010
copper sulfatemetal sulfateemetic;
fertilizer;
sensitiser
1987198737.0low010000
deuteriumdihydrogen1979197945.0low010000
fluorinediatomic fluorine;
gas molecular entity
NMR chemical shift reference compound1972197252.0low010000
chlorinediatomic chlorine;
gas molecular entity
bleaching agent1964197355.5low020000
sulfur trioxidesulfur oxide1998199826.0low001000
galactose1971200731.8low122100
poloxaleneepoxide1993199629.5low002000
vasotocin1988201027.8low033300
barium chloridebarium salt;
inorganic chloride
potassium channel blocker1999199925.0low001000
trolamine salicylate1985200725.3low010200
ammonium chlorideammonium salt;
inorganic chloride
ferroptosis inhibitor1998201219.0low001010
ethionineS-ethylhomocysteineantimetabolite;
carcinogenic agent
1963200345.5low0110100
urobilinogenbilaneshuman metabolite1968196856.0low010000
cephalexinbeta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative
antibacterial drug1998199826.0low001000
tetradecanoylphorbol acetateacetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester
antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
1986201527.9low010431130
fluorideshalide anion;
monoatomic fluorine
1969199847.5low0112000
metergolinecarbamate ester;
ergoline alkaloid
dopamine agonist;
geroprotector;
serotonergic antagonist
1989199432.0low012000
cresyl violet1992199232.0low001000
1-deoxynojirimycin2-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid
anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
2014201410.0low000010
n-n-propylnorapomorphine1985198539.0low010000
iodinehalide anion;
monoatomic iodine
human metabolite2005200519.0low000100
phosphotyrosineL-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine
Escherichia coli metabolite;
immunogen
1998200721.8low002300
phenyl acetatebenzenes;
phenyl acetates
1969199844.4low061000
cetylpyridinium chloride anhydrouschloride salt;
organic chloride salt
antiseptic drug;
surfactant
1998200821.0low101100
chloroprenechloroolefin1989198935.0low010000
ursodeoxycholic acidbile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid
human metabolite;
mouse metabolite
1982202128.1low129101
8-bromo cyclic adenosine monophosphate3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound
antidepressant;
protein kinase agonist
1984200031.0low0511000
transferrin1983198639.5low020000
alkenes2003200321.0low000100
glutamic acidglutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid
Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
1981202026.6low0824970
azidespseudohalide anionmitochondrial respiratory-chain inhibitor1970199046.8low041000
adenosine diphosphate riboseADP-sugarEscherichia coli metabolite;
mouse metabolite
1990200226.4low005200
amoxicillinpenicillin allergen;
penicillin
antibacterial drug1995199529.0low001000
vanadyl sulfatemetal sulfate;
vanadium coordination entity
2005200519.0low000100
clanobutinbenzamides1981199934.0medium011000
5,7-dihydroxytryptamine1985200428.0low012100
etoposidebeta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound
antineoplastic agent;
DNA synthesis inhibitor
202120213.0low000001
substance ppeptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
1960202334.8low0198942982
acetosulfameorganic heteromonocyclic compound;
organonitrogen heterocyclic compound;
oxacycle;
sulfamate ester
environmental contaminant;
sweetening agent;
xenobiotic
1987201224.5low010010
tertatololthiochromane1999199925.0low001000
2,4,5,2',4',5'-hexachlorobiphenylhexachlorobiphenyl2000200024.0low001000
4-methylhistaminearalkylamino compound;
imidazoles
histamine agonist;
metabolite
1981198143.0low010000
phorbol 12,13-dibutyratebutyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone
1988200429.7low011100
hydroxymaprotilin1993199331.0low001000
methyldopaL-tyrosine derivative;
non-proteinogenic L-alpha-amino acid
alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
1974197450.0low010000
bezafibratearomatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes
antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
2003200321.0low100100
diltiazem5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
1994202023.8low005210
ng-nitroarginine methyl esteralpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound
EC 1.14.13.39 (nitric oxide synthase) inhibitor1992201226.1low0011210
deoxynivalenolcyclic ketone;
enone;
primary alcohol;
secondary alpha-hydroxy ketone;
trichothecene;
triol
mycotoxin201220189.2low000080
1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril1982198242.0low010000
quisqualic acidnon-proteinogenic alpha-amino acid1990199034.0low001000
2,3,4,7,8-pentachlorodibenzofuranpolychlorinated dibenzofuran2000200024.0low001000
enkephalin, methionine1981201934.9low14315610
lidofeninamino acid amide2000202013.8medium001140
nitrosobis(2-oxopropyl)amineketone;
nitrosamine
carcinogenic agent1984199731.8low0313000
paroxetinearomatic ether;
benzodioxoles;
organofluorine compound;
piperidines
antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
1994199828.7low103000
captoprilalkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
1996199926.5low002000
oltipraz1,2-dithiole;
pyrazines
angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
1991199133.0low001000
pergolidediamine;
methyl sulfide;
organic heterotetracyclic compound
antiparkinson drug;
dopamine agonist
1986198638.0low010000
colforsinacetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol
adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
1986201327.4low0720910
cefaclor anhydrouscephalosporinantibacterial drug;
drug allergen
2000201118.8low102110
alfentanilmonocarboxylic acid amide;
piperidines
central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
2000200024.0low001000
fomesafenaromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols
agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
1966201334.0low02212920
lovastatindelta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)
anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
2005200519.0low000100
idazoxanbenzodioxine;
imidazolines
alpha-adrenergic antagonist2012201212.0low000010
quinpirolepyrazoloquinolinedopamine agonist1984199135.1low034000
pravastatin3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)
anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
2006200618.0low000100
gepironeN-arylpiperazine1994199430.0low001000
mifepristone3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound
abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
1996201419.0low001010
fura-21989202230.2low0118101
eticlopridesalicylamides2003200321.0low000100
imiquimodimidazoquinolineantineoplastic agent;
interferon inducer
201920195.0low000010
naxagolideorganic heterotricyclic compound;
phenols;
tertiary amino compound
anticonvulsant;
antiparkinson drug;
dopamine agonist
1990199034.0low001000
loxiglumideorganic molecular entity1987201530.2high4016132910
tiagabinebeta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes
anticonvulsant;
GABA reuptake inhibitor
2013201311.0low000010
enadoline1992199232.0low001000
valsartanbiphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid
angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
2012201212.0low000010
adenosineadenosines;
purines D-ribonucleoside
analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
1976200233.4low022100
vanadatestrivalent inorganic anion;
vanadium oxoanion
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
1990199630.3low003000
eddaamino dicarboxylic acid;
ethylenediamine derivative;
glycine derivative;
polyamino carboxylic acid
bacterial xenobiotic metabolite;
chelator
1986198638.0low020000
colestipol1994199430.0low001000
trazodone hydrochloridehydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
1968197751.5low020000
3,4,5,3',4'-pentachlorobiphenylpentachlorobiphenyl;
trichlorobenzene
2000200024.0low001000
glucose, (beta-d)-isomerD-glucopyranoseepitope;
mouse metabolite
2014201410.0low000010
2',7'-dichlorofluorescein2-benzofuransfluorochrome2007200717.0low000100
thiazolyl blueorganic bromide saltcolorimetric reagent;
dye
2005202011.5low000110
n-acetylaspartic acidN-acetyl-L-amino acid;
N-acyl-L-aspartic acid
antioxidant;
human metabolite;
mouse metabolite;
nutraceutical;
rat metabolite
1997199727.0low001000
o-(6)-methylguaninemethylguaninemutagen1992199232.0low001000
pyrrolidine dithiocarbamatedithiocarbamic acids;
pyrrolidines
anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
2001200123.0low000100
4-aminomethylbenzoic acidbenzoic acids2012201212.0low000010
cephalosporin ccephalosporinfungal metabolite1998200025.0low002000
lathosterol3beta-sterol;
C27-steroid;
cholestanoid;
Delta(7)-sterol
human metabolite;
mouse metabolite
2014201410.0low000010
mci-1962008200816.0low000100
cr 13921988199035.0high031000
web 2086organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
1993199331.0low001000
dexloxiglumideglutamic acid derivative1998201018.9high5011000
methacycline1,2-diglyceride1989198935.0low010000
triazoles1,2,3-triazole1988202119.8low011011
medetomidineimidazoles1994199430.0low001000
fluorodeoxyglucose f182-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
2013201311.0low000010
sertralinedichlorobenzene;
secondary amino compound;
tetralins
antidepressant;
serotonin uptake inhibitor
1999200820.5low001100
selfotelnon-proteinogenic alpha-amino acid2000200024.0low001000
delta sleep-inducing peptide1985199235.5low011000
drospirenone3-oxo-Delta(4) steroid;
steroid lactone
aldosterone antagonist;
contraceptive drug;
progestin
2007201314.0low100110
tricaprindecanoate ester;
triglyceride
1992199232.0low001000
tyrosyltyrosinetyrosyltyrosineMycoplasma genitalium metabolite1992202113.3medium402262
n-methylscopolamine1986200329.4low013100
pipequaline1985198539.0low010000
trichlorosucrosedisaccharide derivative;
organochlorine compound
environmental contaminant;
sweetening agent;
xenobiotic
2012201212.0low000010
ubenimex1981199237.0low031000
sulfolithocholylglycinebile acid glycine conjugate;
steroid sulfate
1981198143.0low010000
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate2000200024.0low001000
magnololbiphenyls2009200915.0low000100
honokiolbiphenyls2009200915.0low000100
tetrandrinebisbenzylisoquinoline alkaloid;
isoquinolines
1995199529.0low001000
2-(2-aminoethyl)pyridineaminoalkylpyridine;
primary amine
histamine agonist;
metabolite
1980198044.0low010000
rosiglitazoneaminopyridine;
thiazolidinediones
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
2010201014.0low000100
fluorescein dilaurate1982199537.8low041000
biocytinazabicycloalkane;
L-alpha-amino acid zwitterion;
L-lysine derivative;
monocarboxylic acid amide;
non-proteinogenic L-alpha-amino acid;
thiabicycloalkane;
ureas
mouse metabolite1994201515.5low001630
biotinamidebiotins;
monocarboxylic acid amide
human metabolite2003200321.0low000100
a 8947aromatic ether;
biaryl;
N-sulfonylurea;
pyrazole pesticide;
tetrazoles
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
1997199727.0medium001000
2-(2-aminoethyl)thiazole1,3-thiazoles1990199034.0low001000
5-thio-d-glucose1984200629.0low010100
dimyristoyl diglyceride1,2-diglyceride;
tetradecanoate ester
1993199331.0medium001000
nicotine3-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
1968200439.8low094200
2-chloromercuri-4-nitrophenol1987198737.0low010000
homocysteineamino acid zwitterion;
homocysteine;
serine family amino acid
fundamental metabolite;
mouse metabolite
1997199727.0low001000
8-((4-chlorophenyl)thio)cyclic-3',5'-amp3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
aryl sulfide;
organochlorine compound
protein kinase agonist1997199926.0low002000
dextromoramidemorpholines;
N-acylpyrrolidine
opioid analgesic1963196361.0low020000
butyloxycarbonyl-tryptophyl-methionyl-aspartyl-phenylalaninamide1993199829.0high003000
3-maleimidobenzoyl n-hydroxysuccinimide1984198738.5low020000
benzoylphenylalanine2-(benzoylamino)-3-phenylpropanoic acid;
N-acyl-L-phenylalanine
2013201311.0low000010
n-succinimidyl-3-(4-hydroxyphenyl)propionate1982199634.4low034000
foxes2002200222.0low000100
enkephalinamide-met, ala(2)-1982200330.8low020200
n-hydroxysuccinimide suberic acid ester1983198341.0low010000
suphepa1975197549.0low010000
cobaltcobalt group element atom;
metal allergen
micronutrient1983199537.5low031000
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acidpolyamino carboxylic acid;
tetracarboxylic acid
chelator1992201124.6low006310
1-amino-1,3-dicarboxycyclopentane1997199727.0low001000
chlorateschlorine oxoanion;
monovalent inorganic anion
1994200027.0low002000
enkephalin, d-penicillamine (2,5)-heterodetic cyclic peptidedelta-opioid receptor agonist1996200423.8low002200
u 73122aromatic ether;
aza-steroid;
maleimides
EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor1992201622.9low007230
quin21983198540.0low020000
sr141716amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles
anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
2005201515.3low000510
cp 963451994199430.0low001000
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazoleether;
imidazoles;
monomethoxybenzene
TRP channel blocker2009200915.0low000100
fluo-3xanthene dyefluorochrome1992199928.5low002000
paxillinediterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol
anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
1997200720.8low001300
paxillinediterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol
anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
1997200721.7low001200
cyanates1988198836.0low010000
beta-carboline-3-carboxylic acid ethyl esterbeta-carbolines1986198837.0low020000
beta-n-methylamino-l-alaninediamino acid;
L-alanine derivative;
non-proteinogenic L-alpha-amino acid;
secondary amino compound
bacterial metabolite;
neurotoxin
2013201311.0low000010
fura-2-am1992199331.5low002000
s-ethyl glutathioneoligopeptide1992199232.0low001000
n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine1987198737.0low010000
cgp 353481994199430.0low001000
beta-carboline-3-carboxylic acid methyl esterbeta-carbolines1986199036.0low021000
cv 62091996199628.0low001000
inositol-1,3,4,5-tetrakisphosphateinositol phosphate1994199430.0low001000
l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide1988198836.0low010000
enkephalin, ser(2), leu(5), thr(6)-oligopeptide1999199925.0low001000
procyanidinproanthocyanidin201020236.0low000121
sr 95531methoxybenzenes2000200720.5low001100
sepimostate mesilate1992199232.0low001000
ml 92000200024.0low001000
proanthocyanidin202020204.0low000010
dynorphin (1-8)1986199036.0low021000
kt 5823gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound
EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor1997200523.3low002100
1-hexadecyl-2-acetyl-glycero-3-phosphocholine2-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
1986199830.6low014000
ci 9881990201428.1high0041420
deoxyglucose1974202034.5low02111420
gamma-glutamylphenylalaninedipeptidehuman urinary metabolite201920195.0medium000010
3-monoiodothyronine1983198341.0low010000
aluminum phthalocyanineorganic molecular entity2003200321.0low000100
toosendanin2002200222.0low000100
tyrosyl-prolyl-leucyl-glycinamide2010201014.0low000100
way 100135piperazines1995199529.0low002000
tifluadombenzodiazepine1990199034.0low002000
morphiceptin, n-me-phe(3)-1997199727.0low001000
chymosin1971201630.5low010010
sr 48692N-acyl-amino acid1996199727.5low002000
meglumine iotroxinate1982198242.0low010000
caprylatesfatty acid anion 8:0;
straight-chain saturated fatty acid anion
human metabolite;
Saccharomyces cerevisiae metabolite
1992201222.9low304410
renzapride2005200519.0low000100
mosapridearomatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound
2011201113.0low000010
deramciclane1999199925.0low001000
rb 1011992200728.4medium006100
293b cpd1-benzopyran2008200816.0low000100
egta acetoxymethyl ester2005201215.0low000210
phenylalanyl-leucyl-arginyl phenylalaninamide2000200024.0low001000
a 716231990202127.1high0014011
enkephalin-leu, arg(6)-1997199727.0low101000
sr 27897indolyl carboxylic acid1993201822.1high107420
cyclo(7-aminoheptanoylphenylalanyl-tryptophyl-lysyl-benzylthreonyl)1999200223.7medium002100
pd 1173021991199133.0low001000
rc 30951991199332.0low002000
ym 0221994202120.2medium005121
saclofenorganochlorine compound2000200024.0low001000
luzindoleacetamides;
indoles
melatonin receptor antagonist2004201116.5low000110
inositol 2,4,5-trisphosphate1998199826.0low001000
ru 249261984198440.0low010000
vasotocin, 1-(beta-mercapto-(beta, beta-cyclopentamethylene)propionic acid)-tyr(om3)(2)-orn(8)-1991199232.5low002000
5-chloromethylfluorescein diacetateacetate esterfluorochrome2004200420.0low000100
pyroglutamyl-histidyl-glycine2010201014.0low000100
peroxynitrous acidnitrogen oxoacid2007200717.0low000100
gefitinibaromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201620168.0low000010
cholecystokinin (27-33)1980199239.5high0192000
lhrh, gln(8)-1998199826.0low001000
proctolin1997200025.5low002000
enkephalin-met, arg(6)-phe(7)-organic molecular entity1988198836.0low010000
enkephalin-met, arg(6)-gly(7)-leu(8)-1986198638.0low010000
deltorphin ii, ala(2)-1996199628.0low001000
phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide2005202111.0low000211
kyotorphindipeptide1994199430.0low001000
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-organic molecular entity1997199727.0low001000
cyclic adp-ribosecyclic purine nucleotide;
nucleotide-sugar
metabolite;
ryanodine receptor agonist
1994201620.9low004420
hydroxycitric acidcarbonyl compound1985198539.0low010000
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamidediarylmethane2010201014.0low000100
5-((4,6-dichloro-1,3,5-triazin-2-yl)amino)fluorescein1999199925.0low001000
naadpnicotinic acid dinucleotidecalcium channel agonist;
metabolite;
signalling molecule
2000201119.4low002710
kelatorphan1992199232.0low001000
glycerophosphoinositol 4,5-bisphosphate1985200327.8low011200
glicentin1989202019.5low010010
gyki 536551997199727.0low001000
s 209282000200024.0low001000
sri 630721986198638.0medium010000
n(6)-2-(4-amino-3-iodophenyl)ethyladenosine2002200222.0medium000100
phenylalanyl-leucyl-arginyl-phenylalanine1997199727.0medium001000
cholecystokinin 33 (10-20)1986198837.2high050000
tyrosyl-glycyl-tryptophyl-methionyl-aspartyl-phenylalanyl-glycine1989198935.0medium010000
foy 2511984198440.0medium010000
tyrosyl-seryl(o-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(o-t-butyl)1992199630.2high004000
cholecystokinin (26-33), n-methyl-nle(28,31)-1991199232.5high002000
ksg 5041994199430.0low001000
1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone1991200428.6high0010100
cgp 52432dichlorobenzene1994199629.0low002000
omega-n-methylarginineamino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
1993200327.4low104100
fr 120480N-acyl-amino acid1993200426.7high007300
l 7400931998200223.8high002200
aspartamecarboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester
apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
2003201216.5low100110
xyloseD-xylose1967197552.0low030000
prolineamino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid
algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
1995200920.6low001400
asperlicin casperlicins;
indoles;
organic heterotetracyclic compound
Aspergillus metabolite;
cholecystokinin antagonist
1988198836.0medium010000
peptide elongation factor 22004200918.3low000300
ezetimibeazetidines;
beta-lactam;
organofluorine compound
anticholesteremic drug;
antilipemic drug;
antimetabolite
2012201212.0low000010
phenylalanylargininedipeptidemetabolite2012201212.0low000010
evodiaminebeta-carbolines2002200222.0low000100
arginylargininedipeptideMycoplasma genitalium metabolite1997199727.0low001000
cinacalcet(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound
calcimimetic;
P450 inhibitor
201820186.0low000010
singlet oxygenchalcogen;
monoatomic oxygen;
nonmetal atom
macronutrient202220222.0low000001
platycodin dtriterpenoid saponinmetabolite1997199727.0low001000
cholecystokinin 91987201823.9high146930
jmv 1791993199729.0high004000
technetium tc 99m pentetate1990199730.5low102000
nicotinamide 1,n(6)-ethenoadenine dinucleotide2003200321.0low000100
prolyl-lysyl-glycinamide1983198341.0low010000
biotinbiotins;
vitamin B7
coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
1990201123.5low004510
angiotensin iiamino acid zwitterion;
angiotensin II
human metabolite1967202231.6low1186551
atropine1963201238.7low7172106920
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
1998200124.5low001100
homocysteic acidhomocysteic acidNMDA receptor agonist1997199727.0low001000
antalarminpyrrolopyrimidine;
tertiary amino compound
corticotropin-releasing factor receptor antagonist2003200321.0low000100
histidylleucinedipeptide zwitterion;
dipeptide
metabolite1989198935.0low010000
l 3650311989199333.0high011000
pd 1403761994199430.0medium001000
neomyosuppressin1993199331.0low001000
cholic acid12alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid
human metabolite;
mouse metabolite
1983201228.5low020110
erythritolbutane-1,2,3,4-tetrolantioxidant;
human metabolite;
plant metabolite
1976202220.2low320003
deoxycholic acidbile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid
human blood serum metabolite1972199845.1low092000
estradiol 3-benzoate17beta-hydroxy steroid;
benzoate ester
estrogen receptor agonist;
xenoestrogen
2002201018.0low000300
cortisone11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
human metabolite;
mouse metabolite
1966197651.8low040000
anisomycinmonohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic
anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
1996199628.0low001000
benzofurans1989200031.8low014000
acivicinisoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound
antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
1992199232.0low001000
wortmanninacetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound
anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
1997200721.8low002300
ibogaine1983198341.0low010000
taurochenodeoxycholic acidbile acid taurine conjugatehuman metabolite;
mouse metabolite
2004201316.0low000210
nsc 141537trichothecene201720177.0low000010
leupeptins1981200730.0low010100
lithium chlorideinorganic chloride;
lithium salt
antimanic drug;
geroprotector
1985201431.6low0107210
glycogen1965198550.4low050000
bradykininoligopeptidehuman blood serum metabolite;
vasodilator agent
1967200941.1low0196100
elastinoligopeptide1966196658.0low010000
carnosineamino acid zwitterion;
dipeptide
anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
1980199238.0low011000
epiglucan2009200915.0low100200
oxytocinheterodetic cyclic peptide;
peptide hormone
oxytocic;
vasodilator agent
1980201927.0low2274828110
d-tagatoseD-tagatose2000200024.0low001000
inositol 1,4,5-trisphosphatemyo-inositol trisphosphatemouse metabolite1988201427.1low0128710
ouabain11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone
anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
1972198346.7low070000
casein hydrolysate2011201113.0low000010
puromycinpuromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
1981200235.7low020100
taurolithocholic acidbile acid taurine conjugate;
monocarboxylic acid amide
human metabolite1998202015.0low001320
nitroarginineguanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
1993200424.7low008200
nivalenoltrichothecene2014201410.0low000010
psicose, (d)-isomermonosaccharide202220222.0low100001
strychninemonoterpenoid indole alkaloid;
organic heteroheptacyclic compound
avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
1980198044.0low010000
monensincyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal
antifungal agent;
coccidiostat;
ionophore
1990199133.5low002000
pentazocinebenzazocine1967199642.5low011000
miglitolpiperidines2014201410.0low000010
ryanodine1994200523.7low001200
lignans2009200915.0low000100
devazepide1,4-benzodiazepinone;
indolecarboxamide
antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
1986202129.1high56134950161
diprenorphinemorphinane alkaloid1993200326.0low001100
maleic acidbutenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
202020204.0low000010
acetyl coenzyme aacyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite
1979197945.0low010000
tretinoinretinoic acid;
vitamin A
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
1995200524.0low001100
arachidonic acidicosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
1989201821.8low110310
phosphoramidondeoxyaldohexose phosphate;
dipeptide
bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
1993201520.0low001010
resveratrolresveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
202020204.0low000010
retinolretinol;
vitamin A
human metabolite;
mouse metabolite;
plant metabolite
1975197748.0low020000
latrunculin acyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone
actin polymerisation inhibitor;
metabolite;
toxin
2000200024.0low001000
palmitoleic acidhexadec-9-enoic acidalgal metabolite;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
human blood serum metabolite
2010201312.5low000110
oleic acidoctadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
1963201531.5low72936830
tacrolimusmacrolide lactambacterial metabolite;
immunosuppressive agent
1993201023.3low003300
phenylalanine amideamino acid amide;
phenylalanine derivative
1998199826.0low001000
pectinsD-galactopyranuronic acid1985198837.5low120000
cocainebenzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid
adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
1992201124.4low006410
thapsigarginbutyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone
calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
1992201622.8low0091220
tetragastrinpeptidyl amide;
tetrapeptide
anxiogenic;
human metabolite
1980202131.1medium435481321
lycopeneacyclic caroteneantioxidant;
plant metabolite
2011201113.0low000010
y 27632aromatic amide2006201216.0low000210
adenosine-5'-(n-ethylcarboxamide)adenosines;
monocarboxylic acid amide
adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
2002200222.0low000100
diethylstilbestrololefinic compound;
polyphenol
antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
1989198935.0low010000
h 89N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide2000200522.5low002200
dactinomycinactinomycinmutagen1966200837.4low033100
azaserinecarboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid
antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
1987199632.2low0310000
enkephalin, leucinepentapeptide;
peptide zwitterion
analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
1978202233.7low296591662
benzyloxycarbonylleucyl-leucyl-leucine aldehydeamino aldehyde;
carbamate ester;
tripeptide
proteasome inhibitor2007200717.0low000100
cinnamtannin b-1proanthocyanidincyclooxygenase 2 inhibitor;
plant metabolite
2010201014.0low000100
tyrosine o-sulfatearyl sulfate;
L-tyrosine derivative;
O-sulfoamino acid
human metabolite1981201425.5low037320
sodium bicarbonateone-carbon compound;
organic sodium salt
antacid;
food anticaking agent
1986201226.2low212010
sodium chloratechlorate salt;
inorganic sodium salt
herbicide1994200027.0low002000
dipyroneorganic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
2004200420.0low000100
bromochloroacetic acid2-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
1988200129.5low021100
carbenoxolone sodiumtriterpenoid1977197747.0low010000
cinnamaldehyde3-phenylprop-2-enal;
cinnamaldehydes
antifungal agent;
EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor;
flavouring agent;
hypoglycemic agent;
plant metabolite;
sensitiser;
vasodilator agent
2013201311.0low000010
isomethyleugenolisomethyleugenol1994199529.8low004000
piperinebenzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide
food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
1983198341.0low010000
lypressincyclic peptide1985199433.2low014000
arginine vasopressinvasopressincardiovascular drug;
hematologic agent;
mitogen
1981202129.0low296601
dodecylphosphocholinephosphocholinesdetergent2002200719.5low000200
trilostane17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile
abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
201620168.0low000010
methylatropine1984198440.0low010000
tropisetronindolyl carboxylic acid1993200026.3low003000
n(6)-cyclopentyladenosine2002200222.0low000100
bemesetron2003200321.0low000100
alpha-methyltryptophan, (l)-isomer1992199232.0low001000
phenylthioureathioureasEC 1.14.18.1 (tyrosinase) inhibitor2006201115.5low000110
flunarizinediarylmethane2002200222.0low000100
curcuminaromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol
anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
201820186.0low000010
hc 0300312011201113.0low000010
benztropinediarylmethane1992199232.0low001000
methimazole1,3-dihydroimidazole-2-thionesantithyroid drug1989198935.0low010000
urb 597biphenyls201520159.0low000010
capsaicincapsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
1981201528.4low021271950
metiamideimidazoles1975197748.0low160000
benzotript1981199933.8high035000
thiosemicarbazidehydrazines;
thiocarboxamide;
thioureas
1981198143.0low010000
thioureaone-carbon compound;
thioureas;
ureas
antioxidant;
chromophore
1975199044.8low141000
sodium propionateorganic sodium saltantifungal drug;
food preservative
1993199331.0low001000
D-fructopyranosecyclic hemiketal;
D-fructose;
fructopyranose
sweetening agent1970202218.0low422233
thioacetamidethiocarboxamidehepatotoxic agent1981199337.0low011000
digoxincardenolide glycoside;
steroid saponin
anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
1971197252.5low120000
tamoxifenstilbenoid;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
1990200128.5low101100
sodium taurodeoxycholatebile acid taurine conjugatehuman metabolite1978200729.1low023200
nadp1981201121.5low012710
t 0070907carbonyl compound;
organohalogen compound
201920195.0low000010
estrone sulfate17-oxo steroid;
steroid sulfate
human metabolite;
mouse metabolite
201820186.0low000010
ranitidineC-nitro compound;
furans;
organic sulfide;
tertiary amino compound
anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
1981200134.3low142100
u 0126aryl sulfide;
dinitrile;
enamine;
substituted aniline
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
2012201311.5low000020
pica201120208.5low000020
6-methyl-2-(phenylethynyl)pyridineacetylenic compound;
methylpyridines
anxiolytic drug;
metabotropic glutamate receptor antagonist
2008200816.0low000100
lithiumalkali metal atom1973200635.7low0175200
adrafinildiarylmethane1983198341.0low010000
raclopridesalicylamides1989198935.0low010000
orlistatbeta-lactone;
carboxylic ester;
formamides;
L-leucine derivative
anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
1996201019.3low14031400
quininecinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
1975202224.8low220011
n-benzyloxycarbonyl-valyl-phenylalanine methyl ester2009200915.0medium000100
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester2000201916.3low001410
boc-tyr(s03)-nle-gly-trp-nle-asp-2-phenylethyl ester1992201027.9high0024600
ici 1541291991199133.0low001000
asperlicin1985200634.2high0166200
7-chloro-thiokynurenate2000200024.0medium001000
thioperamideprimary aliphatic amine2001200123.0low000200
u-50488dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine
analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist
1991200227.8low003200
sch 23390benzazepine201620168.0low000010
n(4)-chloroacetylcytosine arabinoside2000200024.0medium001000
a 651861992201022.4high002500
n-benzyloxycarbonyl-leucyl-valyl-glycine diazomethane2002200222.0medium000100
cholecystokinin pentapeptide1988200228.2high012100
cholecystokinin (26-33)1985201132.3high054010
cionin1990201228.8high007010
bay-e 46091981198541.0high020000
ginsenosides201820186.0low000010
cholecystokinin (27-33), tert-butyloxycarbonyl-nle(28,31)-1985199433.3high024000
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosineadenosines;
dicarboxylic acid monoamide;
monocarboxylic acid
adenosine A2A receptor agonist;
anti-inflammatory agent
2002200222.0low000100
6-nitrotryptophan1989198935.0low010000
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxalinenaphthalenes;
sulfonic acid derivative
2005201615.0low000410
ovalbumin1987200528.0low011100
sodium dodecyl sulfateorganic sodium saltdetergent;
protein denaturant
1975197549.0low010000
6-cyano-7-nitroquinoxaline-2,3-dionequinoxaline derivative1992202218.7low003021
fg 9041quinoxaline derivative2000200024.0low001000
alpha-chymotrypsin1966202143.4low913924441
17-ketosteroids1962196262.0low010000
2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinonequinazolines2004201714.5high000740
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolalkylbenzene;
ring assembly
2001201814.5low000110
rhodamine 123organic cation;
xanthene dye
fluorochrome201720177.0low000010
2-mercaptoacetatemonocarboxylic acid anion1990200526.7low002100
sphingosinesphing-4-eninehuman metabolite;
mouse metabolite
1993200326.0low001100
quercetin7-hydroxyflavonol;
pentahydroxyflavone
antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
2014201410.0low000010
bilirubinbiladienes;
dicarboxylic acid
antioxidant;
human metabolite;
mouse metabolite
1959200840.5low144422500
dinoprostoneprostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
1981201226.8low0411320
dinoprostmonocarboxylic acid;
prostaglandins Falpha
human metabolite;
mouse metabolite
1990201323.0low002010
arachidonyltrifluoromethanefatty acid derivative;
ketone;
olefinic compound;
organofluorine compound
EC 3.1.1.4 (phospholipase A2) inhibitor2001200123.0low000100
apigenintrihydroxyflavoneantineoplastic agent;
metabolite
1996199628.0low001000
linoleic acidoctadecadienoic acid;
omega-6 fatty acid
algal metabolite;
Daphnia galeata metabolite;
plant metabolite
1999201316.8low102250
calcitriolD3 vitamins;
hydroxycalciol;
triol
antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
1995199529.0low001000
scopoletinhydroxycoumarinplant growth regulator;
plant metabolite
1975197549.0low010000
vitamin k semiquinone radical2000201718.3low002010
11-cis-retinalretinalchromophore;
human metabolite;
mouse metabolite
2005201315.7low000210
thromboxane a2epoxy monocarboxylic acid;
thromboxanes A
mouse metabolite2000200024.0low001000
rumenic acidoctadeca-9,11-dienoic acid2013201311.0low000010
cholecalciferolD3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone
geroprotector;
human metabolite
1975197549.0low010000
gamma-linolenic acidlinolenic acid;
omega-6 fatty acid
human metabolite;
mouse metabolite;
plant metabolite
1992199232.0low001000
alpha-linolenic acidlinolenic acid;
omega-3 fatty acid
micronutrient;
mouse metabolite;
nutraceutical
2008201213.7low000120
harmineharmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
1981198342.0low030000
genistein7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
1993201124.9low006210
harmanharmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid
anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
1981198242.5low020000
humulenealpha-humulene2010201710.5low000110
chrysin7-hydroxyflavonol;
dihydroxyflavone
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
2008201413.0low000110
daidzein7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
1997199727.0low001000
rottlerinaromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone
anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
2004201615.2low000310
anandamideendocannabinoid;
N-acylethanolamine 20:4
human blood serum metabolite;
neurotransmitter;
vasodilator agent
2007201015.5low000200
ceruleninepoxide;
monocarboxylic acid amide
antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
1976198444.0low020000
plaunotolditerpenoid;
primary alcohol
anti-ulcer drug;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
nephroprotective agent;
plant metabolite;
vulnerary
1994199430.0low001000
iobenguane (131i)2000200024.0low001000
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acidstilbenoid1989198935.0low020000
glyceryl 2-arachidonate2-acylglycerol 20:4;
endocannabinoid
human metabolite2011201113.0low000010
menatetrenonemenaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent
2004200420.0low000100
16,16-dimethylprostaglandin e2cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol
anti-ulcer drug;
gastrointestinal drug;
radiation protective agent
1989198935.0low020000
1-monooleoyl-rac-glycerol1-acylglycerol 18:1;
monooleoylglycerol
plant metabolite1989198935.0low020000
menaquinone 62004200420.0low000100
sphingosine 1-phosphatesphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
2003200321.0low000100
codeinemorphinane alkaloid;
organic heteropentacyclic compound
antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
1962197457.7low030000
oleyl alcoholfatty alcohol 18:1;
long-chain primary fatty alcohol
metabolite;
nonionic surfactant
1989198935.0low110000
granisetronaromatic amide;
indazoles
1996201322.0low002110
hydromorphonemorphinane alkaloid;
organic heteropentacyclic compound
mu-opioid receptor agonist;
opioid analgesic
1962196361.5low020000
nalorphinemorphinane alkaloid1962199048.0low011000
naloxonemorphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol
antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
1978200834.1low34432900
oxymorphonemorphinane alkaloid1994199430.0low001000
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
1996201421.4low004310
topiramatecyclic ketal;
ketohexose derivative;
sulfamate ester
anticonvulsant;
sodium channel blocker
2008201512.5low100110
brefeldin amacrolide antibioticPenicillium metabolite1991201023.5low001100
morphinemorphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound
anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
1962201335.3low374632520
7-benzylidenenaltrexonephenanthrenes2001200123.0low000100
alpha-neoendorphin1984198440.0low010000
anthramycin1988198935.5low020000
atosibanoligopeptide1996201019.8low001300
bc 2641990201228.2high0029210
endomorphin 1oligopeptide2001200521.0low000200
endomorphin 22001200521.0low000200
herbimycin1,4-benzoquinones;
lactam;
macrocycle
antimicrobial agent;
apoptosis inducer;
herbicide;
Hsp90 inhibitor;
tyrosine kinase inhibitor
1996200623.0low001200
kallidinpeptide1967200745.2low030100
gv 150013xbenzodiazepine1999200721.0medium001100
preclamol1992199232.0low001000
l 365260benzodiazepine1989201828.7high041441520
enprostil1995199529.0low001000
lysophosphatidic acid1-acyl-sn-glycerol 3-phosphate2007200717.0low000100
lysophosphatidylcholines1-O-acyl-sn-glycero-3-phosphocholine1974198445.0low020000
cytochalasin bcytochalasin;
lactam;
lactone;
organic heterotricyclic compound
actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
1977198244.5low020000
neurokinin a1985201329.8low065210
neurokinin bpolypeptide1986200827.6low041400
calyculin a1996200423.0low001200
rioprostilaliphatic alcohol1989198935.0low010000
kn 93monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound
EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
2002200222.0low000100
kn 62piperazines1994201917.5low001010
biliverdine1987198737.0low010000
2-oleoylglycerol2-acylglycerol 18:1;
monooleoylglycerol
201520207.0low200030
ag-490catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide
anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
2005200519.0low000100
leadcarbon group element atom;
elemental lead;
metal atom
neurotoxin2004200619.0low000200
methyl 2,5-dihydroxycinnamatecinnamate ester;
hydroquinones;
methyl ester
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
geroprotector;
human urinary metabolite;
plant metabolite
1996199628.0low001000
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyaninecyanine dye;
indolium ion
fluorochrome2007200717.0low000100
diamide1,1'-azobis(N,N-dimethylformamide)2002200222.0low000100
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid2000200024.0low001000
antimonymetalloid atom;
pnictogen
1977197747.0low010000
bariumalkaline earth metal atom;
elemental barium
1971200243.3low041100
rubidiumalkali metal atom1966199446.0low031000
aluminumboron group element atom;
elemental aluminium;
metal atom
1985198539.0low010000
levorphanolmorphinane alkaloid1984198440.0low010000
strontiumalkaline earth metal atom2005200519.0low000100
bismuthmetal atom;
pnictogen
1995200822.5low001100
levallorphanmorphinane alkaloid1991199133.0low001000
dihydromorphinemorphinane alkaloid1990199034.0low001000
arsenicmetalloid atom;
pnictogen
micronutrient1990199034.0low001000
naltrexonecyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound
antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
1985201326.9low039510
dextrorphanmorphinane alkaloid1984198440.0low010000
lasalocidbeta-hydroxy ketone;
monocarboxylic acid;
monohydroxybenzoic acid;
oxanes;
oxolanes;
polyether antibiotic;
secondary alcohol;
tertiary alcohol
bacterial metabolite;
coccidiostat;
ionophore
1977197747.0low010000
methylnaltrexonephenanthrenes2013201311.0low000010
sulfurchalcogen;
nonmetal atom
macronutrient1996200623.0low001100
zimeldinestyrenes1999199925.0low001000
veratrinealkaloid1971199636.6low023000
3-acetyldeoxynivalenoltrichotheceneepitope;
mycotoxin
2014201410.0low000010
dimyristoylphosphatidylcholine1,2-diacyl-sn-glycero-3-phosphocholine;
phosphatidylcholine 28:0;
tetradecanoate ester
antigen;
mouse metabolite
1993200425.5low001100
cysteinecysteiniumfundamental metabolite1967200545.5low050100
thyroninesthyronine1983198341.0low010000
phosphorusmonoatomic phosphorus;
nonmetal atom;
pnictogen
macronutrient1968197453.2low080000
heroinmorphinane alkaloidmu-opioid receptor agonist;
opioid analgesic;
prodrug
1994199430.0low001000
ximelagatranamidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide
anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
2006200618.0low100100
norbinaltorphimineisoquinolines1992200924.2low004200
dermorphinoligopeptide2005200519.0low000100
enkephalin, ala(2)-mephe(4)-gly(5)-1991201026.2low008400
n-methylnaloxone2001200123.0low000100
litorin1980198640.3medium060000
neuromedin c1987200230.5low034100
enkephalinamide-leu, ala(2)-1984198440.0low010000
naltrindole benzofuranmorphinane alkaloid2001200123.0low000100
uroguanylin201720177.0low000010
n-methyllevallorphan1991199133.0low001000
a 713781993200027.4high005000
guanylin201720177.0low000010
delta sleep-inducing peptide, n-tyr-1985198539.0medium010000
pbc 2641989199930.8high015000
trioleintriglycerideCaenorhabditis elegans metabolite;
plant metabolite
1963200941.1low254100
naltrindoleisoquinolines1991199929.4low005000
resiniferatoxincarboxylic ester;
diterpenoid;
enone;
monomethoxybenzene;
organic heteropentacyclic compound;
ortho ester;
phenols;
tertiary alpha-hydroxy ketone
analgesic;
neurotoxin;
plant metabolite;
TRPV1 agonist
2000200024.0low001000
carbocyaninescyanine dye;
organic iodide salt
fluorochrome2007200717.0low000100
ammonium sulfateammonium salt;
inorganic sulfate salt
fertilizer1972197252.0low010000
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid1989200129.2low021100
mastoparanmastoparans;
peptidyl amide
antimicrobial agent1991199133.0low001000
tetrodotoxinazatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid
animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
1971201535.2low04229720
seleniumchalcogen;
nonmetal atom
micronutrient1969198249.7low0290000
octadecylsilane1986198638.0low010000
t 06321999199925.0medium001000
diacetylmonoxime2000200024.0low001000
dizocilpine maleatemaleate salt;
tetracyclic antidepressant
anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
1991202222.5low009331
antimycin aamidobenzoic acid1969199047.5low031000
cholestanolcholestanoid1965197255.5low020000
buniodylcinnamic acids1964196460.0low010000
1-oleoyl-2-acetylglycerol1,2-diglyceride1989198935.0low010000
3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid2011201312.0low000030
manoalidebutenolide;
lactol;
sesterterpenoid
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
metabolite
1995199529.0low001000
igmesine1994199629.0low002000
2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid1997199727.0low001000
pd 1364501994199430.0low001000
pregna-4,17-diene-3,16-dione3-hydroxy steroidandrogen2014201410.0low000010
bc 1971994200127.3high006100
zy 17617b1994199827.7low003000
beta-escin1997201020.5low001100
dihydrexidinephenanthridines2008200816.0low000100
s-nitroso-n-acetylpenicillaminenitroso compound;
nitrosothio compound
nitric oxide donor;
vasodilator agent
2002200222.0low000100
cr 29452004200916.7medium000300
sb 334867-anaphthyridine derivative202020204.0low000010
butylscopolammonium bromide1976200937.5low130100
morphinansisoquinoline alkaloid fundamental parent;
morphinane alkaloid
1991199133.0low001000
ergolinediamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound
1984199135.5low044000
adenosine-3',5'-cyclic phosphorothioatenucleoside 3',5'-cyclic phosphorothioate1994200126.7low002100
sq-23377cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid
calcium ionophore;
metabolite
1988200727.5low0111300
fostriecin2-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol
antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor
2003200321.0low000100
org 27661989199333.0low011000
enkephalin, leucine-2-alanine1984199137.7low021000
nocloprost1993199331.0low001000
enkephalin-leu, ala(2)-arg(6)-1991199133.0low001000
oleoyl-estrone2007200916.0low000200
vildagliptinamino acid amide2014201410.0low000010
rebaudioside abeta-D-glucoside;
rebaudioside;
tetracyclic diterpenoid
sweetening agent201520159.0low100010
bentiromidedipeptidediagnostic agent;
indicator;
reagent
1978199838.4low261000
staurosporineammonium ion derivative1989199930.7low0114000
chloralose1969198548.3low030000
phenylalanyl-valinedipeptidemetabolite201920195.0medium000010
phosphocreatinephosphagen;
phosphoamino acid
human metabolite;
mouse metabolite
1967196757.0low010000
biie 02462012201212.0low000010
butabindide1996199628.0low001000
seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide2005200519.0low000100
jasplakinolidecyclodepsipeptide;
phenols
actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
2007200717.0low000100
sincalideoligopeptide1977202330.4high214373401628510
sincalideoligopeptide1977202332.9high1543733784268
brl 37344monocarboxylic acid2005200519.0low000100
ursodoxicoltaurinebile acid taurine conjugateanti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent
2013201311.0low000010
sr 1461312002201916.8high000310
pentagastrinorganic molecular entity1967201042.6low718336900
mocetinostataminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
2002201717.3low000610
n-(2-naphthalenesulfonyl)aspartyl-(2-phenethyl)amide1995200821.2medium001300
shu 91192005200917.0low000200
pd 1405482001200421.3medium000300
ginsenoside rg3ginsenoside;
glycoside;
tetracyclic triterpenoid
angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
201820186.0low000010
ym-2548902009200915.0low000100
sorbitan monooleatefatty acid ester2007200717.0low100100
bim 230272001200123.0low000100
pasireotidehomodetic cyclic peptide;
peptide hormone
antineoplastic agent2012201212.0low100010
g(m1) gangliosidealpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide
1981198441.5low040000
methionine sulfoxideamino acid zwitterion;
L-methionine S-oxide
Escherichia coli metabolite1981198143.0low010000
fmrfamide1985201328.9low035210
alpha-synuclein201520225.5low000011
eledoisinpeptide1973197947.3low030000
15-acetyldeoxynivalenoltrichotheceneepitope;
mycotoxin
2014201410.0low000010
substance p2003200321.0low000100
isotocin1989198935.0low010000
oxadiazoles1990199034.0low001000
ucn 1028 c1993199927.4low005000
acebutololalpha-D-glucosyl-(1->4)-D-mannopyranose1969200334.7low036100
lactulose1977199939.5low031000
fumiquinazoline afumiquinazoline;
imidazoindole;
pyrazinoquinazoline
2006200618.0low000100
gb-115201120238.3medium000021
potassium cyanatecyanate salt;
one-carbon compound
herbicide1988198836.0low010000
mitoquinone201520159.0low000010
technetium tc 99m disofenin1983201730.9low2712310
technetium tc 99m mebrofenin1997199727.0low002000
chlorocitric acid1985198837.5high020000
veratridine1983199336.3low043000
losartan potassium2013201311.0low000010
xenopsin1982198839.0low020000
calcimycinbenzoxazole1975201236.8low03818210
sepharose1994199430.0low001000
scopolamine hydrobromide1968201239.2low084010
pituitrin1966201634.1low039191240
virginiamycin1991199331.5low004000
inositol 3,4,5-trisphosphate2008200816.0low000100
phytosterols1999199925.0low001000
dihydrotachysterol1975197549.0low010000
acid phosphatase1981199338.8low031000
mefloquine2009200915.0low000100
neosolaniol201720177.0low000010
physalaemin1978199939.8low071000
icatibant1996199628.0low001000
carbon-11 methionine202020204.0low000010
nadorganophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
1970200828.2low110300
cytochrome c-t1987198737.0low010000
calcitonin2001200421.5low000200
cosyntropin1981198143.0low010000
melitten1989198935.0low010000
ceruletideoligopeptidediagnostic agent;
gastrointestinal drug
1970202236.9medium142211072393
motilin1976202234.6medium1387241673
dynorphins1982202128.5low11516631
atrial natriuretic factorpolypeptide1992201127.0low005110
(dtpa-phe(1))-octreotide2012201212.0low000010
gr 823341999199925.0low001000
somatostatin, n-tyr(1)-1984198539.5low020000
somatostatin, tyr(11)-1984198440.0low010000
bombesin, tyr(4)-1992199232.0low001000
cholecystokinin (1-14)1987201128.8high040110
glucagon-like peptide 1 (1-37)1994199430.0low001000
leucosulfakinin1986200133.0high030100
cholecystokinin (26-32), tyr-gly-nle(28,31) phenethyl ester-1991200727.6high008200
perisulfakinin1989198935.0medium010000
nociceptinorganic molecular entity;
polypeptide
human metabolite;
rat metabolite
2004202111.3low000231
cholera toxin, b subunit (50-64)1987198737.0low010000
fibrinopeptide b2009200915.0low000100
gastrin heptadecapeptide, nle(15)-1991199133.0medium002000
omega-conotoxin (conus magus)1990199133.5low002000
glucagon-like peptide 1 (7-36)amide1990200826.0low103200
drosulfakinin ii1988198836.0medium010000
gastrins1964202337.6medium4277131695506
glucagonpeptide hormone1967202339.4low413437038248
big gastrin1985201027.4low065700
beta-endorphin1980200734.5low12616400
somatostatin-281990199034.0low001000
sauvagine1985198539.0low010000
neuropeptide y1983202322.4low1317369473
heliodermin1989199034.5low011000
peptide phi1980199736.3low195000
pancreastatin1988199633.6low065000
iberiotoxin2000200223.0low001100
ac 1872000200620.7low001200
cortistatin 142013201311.0low000010
glucagon-like peptide 1 (7-36)1992201815.0low001020
tannins1974201523.0low010020
oligonucleotides1982199334.6low025000
liraglutidelipopeptide;
polypeptide
glucagon-like peptide-1 receptor agonist;
neuroprotective agent
202220222.0low000002
glucagon-like peptide 11990202311.5low840267517432
gamma-endorphin1987198737.0low010000
alpha-endorphin1981198143.0low010000
incretins201120238.4low100081
c-peptide1978202218.1low13372132
ceruletide diethylamineorganoammonium saltdiagnostic agent;
gastrointestinal drug
1981198143.0medium010000
gastrin 17gastrinantineoplastic agent1981201829.3low21116520
natriuretic peptide, c-type2007200717.0low000100
exendin (9-39)201520159.0low000010
celluloseglycoside1969200338.0low010100
endothelin-12006201613.0low000110
phosphatidylcholines1,2-diacyl-sn-glycero-3-phosphocholine1968200242.3low0114100
chlorophyll achlorophyll;
methyl ester
cofactor2009200915.0low000100
thimerosalalkylmercury compoundantifungal drug;
antiseptic drug;
disinfectant;
drug allergen
1996199628.0low001000
nsc 23766hydrochlorideantiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
2008200816.0low000100
hoe 33342202020204.0low000010
ubiquinone1976201528.5low010010
calpain2002200918.5low000200
lucifer yelloworganic lithium saltfluorochrome1985200629.2low021100
sapogenins2009200915.0low000100
ranatensin1980198044.0low010000
bucladesine3',5'-cyclic purine nucleotide1974200440.0low0266200
osteumorganic molecular entity1983201033.1medium11213200
sodium lactatelactate salt;
organic sodium salt
food acidity regulator;
food preservative
1998199826.0low001000
lactisole2011201113.0low100010
stearates1989198935.0low110000
sodium glutamatemonosodium glutamateflavouring agent1987202219.7low120211
s-adenosylmethionineorganic cation;
sulfonium compound
coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
1999199925.0low001000
picrotoxin1983200434.5low041100
intrinsic factor1974198547.0low040000
egg white1969201828.0low211110
rimorphin1996199628.0low001000
dynorphins1982198242.0low010000
neurotensinpeptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
1978202033.5low71437518130
apelin-13 peptideoligopeptideantihypertensive agent;
autophagy inhibitor;
biomarker;
human metabolite;
neuroprotective agent
2011201312.0low000020
drosulfakinin 11988199532.0medium012000
corazonin protein, insect2007200717.0low000100
jnj-310200282013201311.0low000010
mannans2012201610.0low000020
alexa fluor 546organic heteropentacyclic compoundfluorochrome2008200816.0low000100
taurolithocholic acid 3-sulfatesteroid sulfate oxoanionhuman metabolite2004202012.8medium000320
peptones1965201531.9low112141020
a 9670792013201311.0low000010
l 3652091990199034.0medium001000
piperidines1983201524.8low55151240
exenatide1992202311.9low102023
methylcellulose1974200036.7low121000
vasoactive intestinal peptide1976202336.3low43169235114
natriuretic peptide, brainpolypeptide1996201913.4low001130
ac3174201520187.5high000020
jmv 2361990202123.8high003001
neuromedin b1986200233.6low040100
tetracycline1970197750.0low030000
chlortetracycline1971198645.5low020000
oxytetracycline, anhydrous1974197649.0low020000
minocycline2013201311.0low000010
salicylatesmonohydroxybenzoateplant metabolite1972200732.7low011100
warfarinbenzenes;
hydroxycoumarin;
methyl ketone
1975200633.5low110100
tetronothiodin1992199331.3high003000
omega-agatoxin iva1999199925.0low001000
snx 2301999199925.0low001000
epidermal growth factor1976201432.0low01313410
gastrin-releasing peptide1981201729.8low120321040
kaolinitealuminosilicate mineral;
mixture
antidiarrhoeal drug;
excipient
2010201113.3low000120
vasoactive intestinal peptide, 4-chloro-phe(6)-leu(17)-2000200024.0low001000
charybdotoxin2006200618.0low000100
transforming growth factor beta1992200723.8low001300
semaglutidelipopeptide;
polypeptide
anti-obesity agent;
appetite depressant;
glucagon-like peptide-1 receptor agonist;
hypoglycemic agent;
neuroprotective agent
202220222.0low000001
okadaic acidketal1992200825.5low004200
phosphatidylethanol1995199529.0low001000
deoxynivalenol-3-glucosidetrichothecene2014201410.0low000010
technetium tc 99m lidofenin1979201933.4low1911110
hirudin1990201820.0low001010
cyclin d12012201212.0low000010
caseins1969202327.0low41314872
technetium tc 99m sulfur colloid1990199531.5low002000
gamma2-msh2003200321.0low000100
sdz co 6111993199331.0medium001000
oligomycins1969200736.0low010100
nitrophenols1987198737.0low010000
bassianolidecyclodepsipeptide;
cyclooctadepsipeptide
antineoplastic agent;
fungal metabolite;
insecticide
1988201326.8low030110
carboxypeptidase b1986200630.0low021100
peptide yy2003201811.8low1004120
glucagon-like peptide 21999201912.2low201160
calpastatinpolypeptideEC 3.4.22.52 (calpain-1) inhibitor;
EC 3.4.22.53 (calpain-2) inhibitor
2009200915.0low000100
hyaluronoglucosaminidase1972197252.0low010000
gastrin i1989201922.8medium011110
adrenomedullin1999201020.7low001200
mesotocin1992199232.0low001000
deltakephalin1991199431.5low002000
d-ala(2),mephe(4),met(0)-ol-enkephalin1982198739.0low030000
ginkgolide b1994199430.0low001000
t-2 toxin201720186.5low000020
ht-2 toxin201720177.0low000010
vitamin b 121964198549.4low170000
oxyntomodulin1978202327.0low127141675
transforming growth factor alpha2008200816.0low000100
cyclosporine1993200425.1low004400
triciribine201920195.0low000010
cytochalasin d1990200725.0low003100
antipain1981198143.0low010000
peptide yy1985202315.0medium7011448212120
lactoferrin1977198642.7low030000
cholecystokinin 391983200935.9high0206200
digitonin1975198940.3low030000
protopanaxadiol2009200915.0low000100
fusarenon-x2014201410.0low000010
technetium tc 99m medronate1984198440.0low010000
muramidase1970202338.4low040001
somatostatin, trp(8)-1984198440.0low010000
protopanaxatriol2009200915.0low000100
cyclic gmp3',5'-cyclic purine nucleotide;
guanyl ribonucleotide
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
1974200642.9low0574200
deoxyinosinepurine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
1985198539.0low010000
guanosine diphosphateguanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate
Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
1980201520.0low010120
guanosine triphosphateguanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate
Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
1974200435.5low077100
guanine2-aminopurines;
oxopurine;
purine nucleobase
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1992199232.0low001000
inosineinosines;
purines D-ribonucleoside
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1975198544.0low020000
inosine triphosphateinosine phosphate;
purine ribonucleoside 5'-triphosphate
Escherichia coli metabolite;
human metabolite;
mouse metabolite
1993199331.0low002000
folic acidfolic acids;
N-acyl-amino acid
human metabolite;
mouse metabolite;
nutrient
1974197450.0low010000
cyclic imp3',5'-cyclic purine nucleotide;
nucleoside 3',5'-cyclic phosphate
mammalian metabolite;
Saccharomyces cerevisiae metabolite
1982198242.0low010000
guanosine 5'-o-(3-thiotriphosphate)nucleoside triphosphate analogue1990200527.9low0013200
7-methylguanine7-methylguanine1992199232.0low001000
clozapinebenzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound
adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
1983201828.5low023010
dacarbazinedacarbazine2005200519.0low000100
ganciclovir2-aminopurines;
oxopurine
antiinfective agent;
antiviral drug
1999199925.0low001000
olanzapinebenzodiazepine;
N-arylpiperazine;
N-methylpiperazine
antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
2010201213.0low000230
guanylyl imidodiphosphatenucleoside triphosphate analogue1977200537.7low082100
nicotinamide guanine dinucleotide2003200321.0low000100
tegaserodcarboxamidine;
guanidines;
hydrazines;
indoles
gastrointestinal drug;
serotonergic agonist
2005200718.0low000200
1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3h)-one1989198935.0low010000
guanosine 5'-o-(2-thiodiphosphate)nucleoside diphosphate analogue1980201520.0low010120
trypan blue1991199531.0low002000
clozapine n-oxidedibenzodiazepine201820186.0low000010
gtp gamma-4-azidoanilide1990199034.0low001000
8-aminoadenosine cyclic 3',5'-(hydrogen phosphate) 5'-ribofuranosyl ester1998199826.0medium002000
dibutyryl cyclic gmp1977199040.8low0322000
crt 00661012011201113.0low000010
cholestyramine resin1971201433.9low3813110
eye1984199336.3low042000
fructooligosaccharideoligosaccharide2003201216.5low100110
maltodextrin2009201313.0low100110
cortagine2009200915.0low000100
carbidopa1990199233.0low002000
pd 1351581990200426.7high0016400
concanavalin a1977201130.0low010010
trypsinogen1965202036.4low047181130
phosphorus radioisotopes1973198744.8low060000
preproenkephalin1985202123.6low047321
leptin1997202215.9low802195525
pyrimidinones1990200724.5low002200
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
(pPNET) Peripheral Primitive Neuroectodermal Tumors01989199432.5low015000
47,XX,+2101991199133.0low001000
A-V Dissociation01966196658.0low010000
Abdomen, Acute02000200024.0low001000
Abdominal Cramps01971201134.9low184110
Abdominal Injuries01964197952.5low020000
Abdominal Migraine01984202023.9low030220
Abdominal Pain01990202020.5low40148100
Abnormalities, Autosome01971197153.0low010000
Abnormalities, Congenital01984198440.0low010000
Absence Seizure01980202330.3low01110211
Absence Status02007202310.2low000211
Acalculous Cholecystitis02003201118.8low100310
Acetonemia0200820208.3low200120
Achalasia01967202040.5low1101020
Ache01969202331.5low654282771
Achlorhydria01968197951.0low050000
Acidosis, Lactic0201620168.0low000010
Acinar Carcinoma01997200224.5low001100
Acoustic Neuroma01990199034.0low001000
Acromegaly01987200132.1low227100
Action Tremor01983198540.0low020000
Active Hyperemia01968200339.8low031100
Acute Brain Injuries01997201519.0low001210
Acute Cholecystitis02003200917.7low100300
Acute Confusional Senile Dementia01981202333.5low0136021
Acute Disease01968202232.4low564563145
Acute Edematous Pancreatitis01960202239.2low535510757165
Acute Hepatic Failure01996199628.0low001000
Acute Hypercapnic Respiratory Failure02000200024.0low001000
Acute Kidney Failure01970197951.3low160000
Acute Kidney Injury01970197951.3low160000
Acute Liver Injury, Drug-Induced02003201716.3low000210
Acute Necrotizing Pancreatitis02003201614.4low100530
Acute Post-operative Pain01989199731.3low212000
Acute Post-Traumatic Stress Disorder01999201514.7low001020
Acute-Phase Reaction02000200024.0low001000
Addiction, Opioid01984198440.0low010000
Addison Disease01976197648.0low010000
Addison's Anemia01968198550.1low180000
Addison's Disease01976197648.0low010000
Adenocarcinoma01979201730.0low2814520
Adenocarcinoma, Basal Cell01979201730.0low2814520
Adenocarcinoma, Mucinous02001200123.0low000100
Adenoma01972201433.7low062110
Adenoma, alpha-Cell01988199631.3low012000
Adenoma, Basal Cell01972201433.7low062110
Adenoma, beta-Cell01983201228.4low023110
Adenoma, Bile Duct01985199335.0low021000
Adenoma, Islet Cell01968199742.5low0165000
Adenoma, Prostatic01993199331.0low001000
Adenomatosis, Familial Endocrine01973199443.0low021000
Adhesions, Tissue01967196757.0low010000
Adipocere01991200924.6low003200
Adjuvant Arthritis01985201026.5low010100
Adolescent Obesity0201820214.5low100011
Adrenal Cancer01973198944.7low030000
Adrenal Gland Hyperfunction01997201617.5low001010
Adrenal Gland Hypofunction01990199034.0low001000
Adrenal Insufficiency01990199034.0low001000
Adrenocortical Hyperfunction01997201617.5low001010
Adult Neuronal Ceroid Lipofuscinosis02002200222.0low000100
Adult Premature Aging Syndrome01976197648.0low010000
Affective Disorders01989201818.8low010120
Affective Psychosis, Bipolar01982201428.2low031020
Afferent Loop Syndrome01970197054.0low010000
Age-Related Memory Disorders02003201317.0low100210
Age-Related Osteoporosis02006201314.5low000110
Aggression01984202217.6low010321
Aging01967202329.8low741392192
Agoraphobia01994199430.0low101000
Agyria-Pachygyria-Band Spectrum02008202010.0low000110
AIRE Deficiency02001200123.0low000300
Airway Hyper-Responsiveness0202320231.0low000001
Akinetic-Rigid Variant of Huntington Disease01980199240.3low081000
Alactasia01975198444.5low020000
Alcohol Abuse01964202139.8low25511701
Alcohol Drinking01972202129.2low063501
Alcohol Problem02003200321.0low000100
Alcohol Withdrawal Associated Autonomic Hyperactivity02003200321.0low000100
Alcohol-Related Disorders02003200321.0low000100
Alcoholic Cirrhosis01978199740.1low061000
Alcoholic Fatty Liver01993199331.0low001000
Alcoholic Intoxication01977197747.0low010000
Alcoholic Liver Diseases01981199038.5low011000
Alcoholic Pancreatitis01997200820.8low103500
Alcoholism01964202139.8low25511701
Alkalosis01968196856.0low110000
Allergic Encephalomyelitis02011201113.0low000010
Allergic Reaction01966196956.5low020000
Allergy, Drug01972197849.0low020000
Allergy, Food01984200625.7low010200
Allergy, Milk02006200618.0low000100
Allodynia01994202216.4low2051491
Allotriophagy0201120208.5low000020
Alloxan Diabetes01968202127.6low01112851
alpha 1-Antitrypsin Deficiency01982198242.0low010000
ALS - Amyotrophic Lateral Sclerosis01968198943.8low050000
Altitude Hypoxia02000201315.3low001020
Altitude Sickness02000201315.3low001020
Alveolitis, Fibrosing01971197153.0low010000
Alzheimer Disease01981202333.5low0136021
Amentia01981198242.5low060000
American Trypanosomiasis01978198344.0low030000
Amino Acid Metabolism Disorders, Inborn01980198044.0low010000
Amnesia01987198936.0low020000
Amnesia-Memory Loss01987198936.0low020000
Amphetamine Abuse02006201513.5low000110
Amphetamine-Related Disorders02006201513.5low000110
Amyloid Neuropathies01994199430.0low001000
Amyloidosis01964196460.0low010000
Amyotrophic Lateral Sclerosis01968198943.8low050000
Anankastic Personality02004200420.0low000100
Anaplastic Astrocytoma01988199630.6low014000
Anasarca01974200736.0low042100
Anemia, Hemolytic01967196757.0low010000
Anemia, Hemolytic, Acquired01967196757.0low010000
Anemia, Megaloblastic01974197450.0low010000
Anesthesia01973202031.2low01211620
Angioblastic Meningioma02005200519.0low000100
Angiogenesis, Pathologic01985201721.7low010110
Angiostrongylus Infections02002200321.5low000200
Angle's Classification0202220222.0low000001
Anochlesia01980198541.7low060000
Anorexia01981202320.5low142522172
Anorexia Nervosa01982201627.2low246520
Anoxemia01977202117.5low211141
Anoxia, Brain01985198539.0low010000
ANS (Autonomic Nervous System) Diseases01985200930.2low014100
Anterior Cerebral Circulation Infarction0201720177.0low000010
Anterior Choroidal Artery Infarction01994199430.0low001000
Anterior Circulation Transient Ischemic Attack01990199034.0low001000
Antibody Deficiency Syndrome01975197549.0low010000
Anxiety01990202120.1low603435182
Anxiety Disorders01989202024.3low2214640
Anxiety Neuroses01989202024.3low2214640
Aortic Arteritis, Giant Cell01999199925.0low001000
Apnea, Obstructive Sleep02008200816.0low000100
Apoplexy0200120238.0low000112
Appendiceal Cancer01977198941.0low020000
Appendiceal Neoplasms01977198941.0low020000
Appetite Disorders01981201628.0low0102820
Apudoma01979198044.7low030000
Aqueductal Stenosis01988201125.0low011010
Arachnoidal Cerebellar Sarcoma, Circumscribed01999199925.0low001000
Argentaffinoma01973200139.6low082100
Arteriosclerosis01970198447.0low020000
Arthritis01985200725.3low010200
Arthritis, Rheumatoid01964196460.0low010000
Ascariasis01990199034.0low001000
Ascites01970197253.0low020000
Aseptic Necrosis of Femur Head0201920195.0low000010
Asphyxia Neonatorum01997199727.0low001000
Aspiration, Respiratory02012201212.0low000010
Asthenia01969196955.0low010000
Asthma01986202324.7low020001
Asthma, Bronchial01986202324.7low020001
Asthma, Exercise-Induced01986198638.0low010000
Astrocytoma01988199630.6low014000
Astrocytoma, Grade IV01996201419.8low001210
Astrocytosis01994199430.0low001000
Asymmetric Diabetic Proximal Motor Neuropathy01988200930.6low024100
Ataxia01993202316.0low001001
Atherosclerotic Parkinsonism01986199135.0low012000
Atresia, Biliary01988198836.0low010000
Atrial Fibrillation02006200618.0low100100
Atrophy01972202135.6low0102301
Atrophy, Muscle01989198935.0low010000
Atypical Ductal Hyperplasia01975199338.8low031000
Audiogenic Epilepsy02000200024.0low002000
Aura01981201826.2low046520
Auricular Fibrillation02006200618.0low100100
Autoimmune Diabetes01963201838.9low0124110
Autoimmune Disease01968196856.0low010000
Autoimmune Diseases01968196856.0low010000
Autolysis01977197747.0low010000
Autosomal Dominant Cerebellar Ataxia, Type II0201620234.0low000012
Autosomal Dominant Juvenile Parkinson Disease0201520216.0low000011
Autotomy Human01993199331.0low001000
Avitaminosis01981198143.0low010000
Back Ache02013201311.0low000010
Back Pain02013201311.0low000010
Bacterial Disease01989200427.5low010100
Bacterial Infections01989200427.5low010100
Bacterial Infections, Gram-Negative01997199727.0low001000
Bacterial Overgrowth Syndrome01971197153.0low010000
Behavior Disorders01975201833.6low0101120
Benign Meningeal Neoplasms02005200519.0low000100
Benign Neoplasms01973202025.7low088780
Benign Neoplasms, Brain01992201522.2low005220
Benign Psychomotor Epilepsy, Childhood01992202313.9low002342
Benign Supratentorial Neoplasms01988198836.0low010000
Bertielliasis02005200519.0low000100
Bilateral Headache01969199343.0low011000
Bile Duct Cancer01960199644.5low083000
Bile Duct Diseases01979198641.7low030000
Bile Duct Neoplasms01960199644.5low083000
Bile Duct Obstruction01966201336.0low02015510
Bile Duct Obstruction, Extrahepatic01979200335.5low040200
Bile Reflux01980199638.4low053000
Biliary Atresia01988198836.0low010000
Biliary Calculi01969201921.4low1511080
Biliary Cirrhosis01973199739.8low022000
Biliary Dyskinesia01963202334.6low029127121
Biliary Fistula01964200346.8low0100100
Biliary or Urinary Stones01968197751.3low070000
Biliary Tract Cancer01986201328.6low032110
Biliary Tract Diseases01959200945.4low36510500
Biliary Tract Neoplasms01986201328.6low032110
Binge Eating01986201925.4low236520
Binge-Eating Disorder0201920195.0low100010
Bipolar Disorder01982201428.2low031020
Birth Weight01973201230.2low013010
Bladder Diseases02012201212.0low000010
Bleeding01986200629.4low033200
Blepharoptosis01980198542.0low050000
Blood Poisoning02003201415.5low000110
Blood Pressure, High01985202116.6low012151
Blood Pressure, Low01986201328.0low020010
Blood Protein Disorders01972197351.5low020000
Blunt Injuries01996199727.5low002000
Body Weight01967202327.0low9737767452
Bone Cancer02004200718.5low000200
Bone Neoplasms02004200718.5low000200
Borna Disease01988198836.0low010000
Bovine Diseases01998200224.0low001100
Bowel Diseases, Inflammatory01995200822.5low002200
Bradyarrhythmia01995200225.5low001100
Bradycardia01995200225.5low001100
Brain Concussion01996199628.0low001000
Brain Diseases01981198143.0low010000
Brain Disorders01981198143.0low010000
Brain Edema02000200024.0low001000
Brain Infarction0201720177.0low000010
Brain Inflammation0201720177.0low000010
Brain Injuries01997201519.0low001210
Brain Ischemia01987199334.0low011000
Brain Neoplasms01992201522.2low005220
Brain Swelling02000200024.0low001000
Brain Vascular Disorders02001200123.0low000100
Breast Cancer01990201625.8low003010
Breast Neoplasms01990201625.8low003010
Bronchial Neoplasms01979197945.0low010000
Bronchospasm, Exercise-Induced01986198638.0low010000
Bronze Diabetes01963198652.6low090000
Bruxism01983198341.0low010000
Bulbar Palsy01989198935.0low010000
Bulimia01986201925.4low236520
Bulimia Nervosa02006201414.0low200440
Burns01970197054.0low110000
Cachexia02000201913.7low001020
Cacosmia0201620168.0low000010
Calcification, Pathologic01966198948.6low0170000
Calcinosis01966198948.6low0170000
Calcinosis-Raynaud Phenomenon-Sclerodactyly-Telangiectasia01999199925.0low001000
Cancer of Colon01964201532.9low022210
Cancer of Digestive System01988199433.0low011000
Cancer of Duodenum01964200340.7low020100
Cancer of Endocrine Gland01998199826.0low001000
Cancer of Esophagus01980201729.0low020010
Cancer of Gallbladder01971202333.8low041001
Cancer of Gastrointestinal Tract01972201231.0low064320
Cancer of Intestines01978201628.4low027010
Cancer of Kidney01999201517.0low001010
Cancer of Liver01968202325.6low053132
Cancer of Lung01989202226.6low037111
Cancer of Nose01984198440.0low010000
Cancer of Ovary01981199733.7low012000
Cancer of Pancreas01960202138.9low61467518101
Cancer of Parathyroid01973197649.5low020000
Cancer of Pituitary01979201431.2low064210
Cancer of Prostate0201620168.0low000010
Cancer of Rectum01977199538.7low021000
Cancer of Stomach01972201931.0low0147250
Cancer of the Thymus02001200123.0low000100
Cancer of the Thyroid01975202029.9low069230
Cancer of the Uterus01984198440.0low010000
Cancer of the Vulva01983198341.0low010000
Canine Diseases0200720209.7low000120
Carcinogenesis0202320231.0low000001
Carcinoid Tumor01973200139.6low082100
Carcinoma01967201739.7low0107010
Carcinoma 256, Walker01984198440.0low010000
Carcinoma in Situ01991202314.7low001011
Carcinoma, Acinar Cell01997200224.5low001100
Carcinoma, Anaplastic01967201739.7low0107010
Carcinoma, Bronchial01989198935.0low010000
Carcinoma, Bronchogenic01989198935.0low010000
Carcinoma, Colloid02001200123.0low000100
Carcinoma, Ductal, Breast02001200123.0low000100
Carcinoma, Ductal, Pancreatic0202120213.0low000001
Carcinoma, Epidermoid01983198341.0low010000
Carcinoma, Hepatocellular0202120232.0low000002
Carcinoma, Intraductal, Noninfiltrating01975199338.8low031000
Carcinoma, Intraepithelial01991202314.7low001011
Carcinoma, Medullary01995201223.0low003210
Carcinoma, Neuroendocrine0201520159.0low000010
Carcinoma, Non-Small Cell Lung01994202216.0low001001
Carcinoma, Non-Small-Cell Lung01994202216.0low001001
Carcinoma, Oat Cell01977200231.6low037100
Carcinoma, Pancreatic Ductal0202120213.0low000001
Carcinoma, Papillary01996200125.5low001100
Carcinoma, Small Cell01977200231.6low037100
Carcinoma, Small Cell Lung0202020204.0low000010
Carcinoma, Squamous Cell01983198341.0low010000
Cardiac Failure0201520196.8low000040
Cardiometabolic Syndrome02007201712.0low100240
Cardiovascular Diseases0201220169.3low100030
Cardiovascular Pregnancy Complications01994199430.0low001000
Cardiovascular Stroke0201720205.3low000030
Cat Diseases01996202016.0low001010
Celiac Disease01963202243.8low2635521
Celiac Sprue01963202243.8low2635521
Cell Transformation, Neoplastic01989202028.2low022010
Cellulitis01996199628.0low001000
Central Hypothyroidism01981198939.0low020000
Central Nervous System Disease01983200926.3low010200
Central Nervous System Diseases01983200926.3low010200
Cephalgia, Vascular01989198935.0low010000
Cerebral Concussion01996199628.0low001000
Cerebral Infarction01994199430.0low001000
Cerebral Ischemia01987199334.0low011000
Cerebral Primitive Neuroectodermal Tumor01999199925.0low001000
Cerebral Pseudosclerosis01978198841.0low020000
Cerebrovascular Disorders02001200123.0low000100
Chagas Disease01978198344.0low030000
Chemical and Drug Induced Liver Injury02003201716.3low000210
Chemical Dependence01983202024.1low013310
Chemical Sensitivities, Multiple02001200123.0low000100
Chemodectoma01989198935.0low010000
Cholangioma01985199335.0low021000
Cholangitis01964201036.3low020100
Cholecystitis01964201936.6low33721740
Cholecystitis, Acute02003200917.7low100300
Cholecystoduodenal Fistula01968199748.2low051000
Cholecystolithiasis02004200420.0low000200
Cholelithiasis01964202036.7low1273551120
Cholera01967197553.3low030000
Cholera Infantum01966202238.4low23971121
Cholestasis01966201336.0low02015510
Choline Deficiency01980199037.2low041000
Chorea01990199034.0low101000
Chorea Disorders01990199034.0low101000
Choreoathetosis Self-Mutilation Hyperuricemia Syndrome01983198341.0low010000
Chromosomal Translocation0201620168.0low000010
Chromosomal Triplication01984198440.0low010000
Chronic Disease01966201440.6low10239602020
Chronic Hepatitis02003200321.0low000200
Chronic Idiopathic Intestinal Pseudo-Obstruction01982201526.8low020110
Chronic Illness01966201440.6low10239602020
Chronic Insomnia0202320231.0low000001
Chronic Kidney Failure01970200445.2low0110100
Chronic Liver Failure0201820186.0low000010
Chronic Lung Injury01994201022.0low001100
Chronic Pain0202220222.0low000001
Chronic Pancreatitis01960202131.6low170731
Circulatory Collapse01986199534.0low021000
Cirrhoses, Experimental Liver01983199933.8low022000
Cirrhosis0201420235.0low100022
Cirrhosis, Liver01963202248.5low1382001
Claustrophobia01994199927.0low003000
Cocaine Abuse02000200223.0low001100
Cocaine-Related Disorders02000200223.0low001100
Cocarcinogenesis01985199433.5low013000
Cognition Disorders02010201213.0low000110
Colicky Pain01990202020.5low40148100
Colitis02003200321.0low000100
Colitis Gravis01964201533.3low031210
Colitis, Granulomatous01970202027.5low234120
Colitis, Mucous02006202312.4low200852
Colitis, Ulcerative01964201533.3low031210
Colon Diverticula01975197549.0low010000
Colonic Diseases01982198242.0low010000
Colonic Diseases, Functional01972200139.1low4118100
Colonic Diverticulitis02009200915.0low000100
Colonic Inertia01969201829.3low236310
Colonic Neoplasms01964201532.9low022210
Colorectal Cancer01991202320.8low105511
Colorectal Neoplasms01991202320.8low105511
Combat Disorders0201520159.0low000010
Common Bile Duct Diseases01981200033.3low057000
Common Bile Duct Neoplasms01991199730.3low103000
Compensatory Hyperinsulinemia01967200827.9low425300
Complication, Postoperative01964201736.9low51811320
Complications of Diabetes Mellitus01968200045.7low092000
Complications, Pregnancy01973201235.2low030110
Compulsive Eating0201920233.0low000011
Concussive Convulsion01990199034.0low001000
Condition, Preneoplastic01978201431.3low035010
Congenital Erythropoietic Porphyria01995199529.0low001000
Congenital Myotonic Dystrophy01962196262.0low010000
Connective Tissue Diseases01996199628.0low001000
Constipation01969201829.3low236310
Constricted Pupil01990199034.0low001000
Constriction, Pathologic01981200630.0low022200
Constriction, Pathological01981200630.0low022200
Convalescence01967196757.0low010000
Cornea Injuries01998199826.0low001000
Corneal Injuries01998199826.0low001000
Coronary Disease01973198843.5low020000
Coronary Heart Disease01973198843.5low020000
Corpus Luteum Cyst01970197054.0low010000
Cramp01974197450.0low010000
Cranial Nerve X Diseases02014201410.0low000010
Craniopharyngioma02014201410.0low000010
Craniopharyngioma, Adamantinous02014201410.0low000010
Critical Illness02002201914.5low3001040
Crohn Disease01970202027.5low234120
Cruveilhier-Baumgarten Syndrome01978198343.0low030000
Curling Ulcer01967200245.2low7759200
Cushing Syndrome01987201428.8low012010
Cushing's Syndrome01987201428.8low012010
Cyst01987198737.0low010000
Cystadenocarcinoma01981198143.0low010000
Cystadenoma01981198143.0low010000
Cystic Fibrosis01963199943.6low1326000
Cystic Fibrosis of Pancreas01963199943.6low1326000
Cytomegalovirus02008200816.0low000100
Decerebrate Posturing01985200031.0low014000
Deficiency, Folic Acid01972199540.5low011000
Deficiency, Protein01968200944.0low041100
Deficiency, Yang02007200717.0low000100
Degenerative Diseases, Central Nervous System0201520225.5low000011
Deglutition Disorders01962196262.0low010000
Dehydration01974200938.5low030100
Delayed Effects, Prenatal Exposure01994201715.0low001020
Dementia01981198242.5low060000
Dementia Multi-Infarct01996199628.0low001000
Dementia Praecox01981202132.9low113615541
Depression01994202311.4low101562
Depression, Endogenous01981202328.8low173221
Depression, Involutional01999200820.5low001100
Depressive Disorder01981202328.8low173221
Depressive Disorder, Major01999200820.5low001100
Dermatitis, Eczematous01974197450.0low010000
Dermatoses01982198242.0low010000
Diabetes Insipidus01994199430.0low001000
Diabetes Mellitus01963202240.5low15211551
Diabetes Mellitus, Adult-Onset01983202315.0low64134238
Diabetes Mellitus, Type 101963201838.9low0124110
Diabetes Mellitus, Type 201983202315.0low64134238
Diabetic Angiopathies01971197153.0low010000
Diabetic Glomerulosclerosis01971197153.0low010000
Diabetic Nephropathies01971197153.0low010000
Diabetic Neuropathies01988200930.6low024100
Diaphragmatic Hernia01968200044.0low021000
Diarrhea01963202241.0low5263331
Diarrhea, Infantile01979198144.0low020000
Diarrheogenic Islet Cell Tumor01986199632.0low012000
Diathesis01998200920.5low001100
Diffuse Myofascial Pain Syndrome02000200024.0low001000
Digestive System Diseases01980199638.5low062000
Digestive System Disorders01980199638.5low062000
Digestive System Neoplasms01988199433.0low011000
Dilatation, Pathologic01984198440.0low010000
Disease01960199455.6low041000
Disease Exacerbation01999201615.3low002340
Disease Models, Animal01975202318.6low0163248469
Disease, Pulmonary02008200816.0low000100
Diseases of Endocrine System01976199141.0low041000
Diseases, Metabolic02007201115.0low000110
Diseases, Occupational01984198539.5low020000
Disruptive, Impulse Control, and Conduct Disorders02007200717.0low000100
Diverticula01970197153.5low020000
Diverticulum, Colon01975197549.0low010000
Down Syndrome01991199133.0low001000
Drug Hypersensitivity01972197849.0low020000
Drug Overdose02002200819.0low000200
Drug Refractory Epilepsy0201620168.0low000010
Drug Withdrawal Symptoms01990201025.7low00181000
Dumping Syndrome02013201311.0low000010
Duodenal Diseases01967201543.1low0111110
Duodenal Obstruction01994199430.0low001000
Duodenal Reflux01984199536.1low065000
Duodenal Ulcer01967200245.2low7759200
Duodenitis01991199232.5low002000
Dysgeusia0202320231.0low100001
Dyskinesia Syndromes01975197549.0low010000
Dyskinesia, Drug-Induced01983201525.3low011010
Dyskinesia, Medication-Induced01983201525.3low011010
Dyspepsia01969202020.1low2141150
Dysphagia01962196262.0low010000
Dystonia01999199925.0low001000
E coli Infections01979198641.5low020000
Ectopic Hormone Syndromes01973199243.5low051000
Ectopic Pregnancy01970197054.0low010000
Eczema01974197450.0low010000
Edema01974200736.0low042100
EHS Tumor01984198440.0low010000
Electrolytes01963200341.5low1217100
Elevated Cholesterol02002202115.5low000411
Emaciation01972197451.0low020000
Embolism02014201410.0low000010
Embolus02014201410.0low000010
Emesis01968201427.9low033230
Empyema, Gall Bladder01964201936.6low33721740
Encephalitis0201720177.0low000010
Encephalopathy, Hepatic01983199236.0low022000
End Stage Liver Disease0201820186.0low000010
Endocrine Gland Neoplasms01998199826.0low001000
Endocrine System Diseases01976199141.0low041000
Endometrioma01971198745.0low020000
Endometriosis01971198745.0low020000
Endotoxemia01997201317.0low001020
Endotoxin Shock01986201723.4low022120
Enlarged Liver01975197549.0low010000
Enteric Fever01964196460.0low020000
Enteritis01964200739.9low041200
Enterocolitis, Necrotizing02002200222.0low000100
Enteropathy, Exudative01968196955.5low020000
Epilepsy01981201826.2low046520
Epilepsy, Reflex02000200024.0low002000
Epilepsy, Temporal Lobe01992202313.9low002342
Erosive Duodenitis01991199232.5low002000
Erythema01974197450.0low010000
Escherichia coli Infections01979198641.5low020000
Esophageal Achalasia01967202040.5low1101020
Esophageal and Gastric Varices01976198344.5low020000
Esophageal Diseases01976197648.0low020000
Esophageal Dysmotility02005202012.7low000210
Esophageal Hernia01985198539.0low010000
Esophageal Neoplasms01980201729.0low020010
Esophageal Reflux01972202128.7low674721
Esophageal Varices01976198344.5low020000
Esophagitis, Peptic01985198539.0low010000
Esophagitis, Reflux01985198539.0low010000
Ewing Sarcoma02004201316.0low000210
Exertional Heat Illness01999202211.0low001011
Exocrine Pancreatic Insufficiency01980202032.7low42417310
Experimental Mammary Neoplasms01994199430.0low001000
Experimental Neoplasms01979199934.9low034000
Experimental Radiation Injuries01976197648.0low010000
Extravascular Hemolysis01984198440.0low010000
Failure to Thrive02002201515.5low100110
Fasciola Infection01998199826.0low001000
Fascioliasis01998199826.0low001000
Fasting Hypoglycemia01969201440.3low1111030
Fatigue01997199727.0low001000
Fatty Liver01967201335.0low042020
Fatty Liver, Nonalcoholic0201220227.0low100022
Feeding and Eating Disorders01981201628.0low0102820
Fetal Death02002200222.0low000100
Fetal Growth Restriction02011201212.5low000020
Fetal Growth Retardation02011201212.5low000020
Fever01994200723.1low004400
Fibroid02012201212.0low000010
Fibromyalgia02000200024.0low001000
Fibrosis0201420235.0low100022
Fish Diseases02003200520.0low000200
Fistula01971200239.7low085100
Flatulence02001200123.0low100100
Flatus02001200123.0low100100
Folic Acid Deficiency01972199540.5low011000
Food Hypersensitivity01984200625.7low010200
Froehlich's Syndrome01985199235.5low111000
Gall Bladder Diseases01960202339.6low25017642
Gallbladder Dyskinesia01963202334.6low029127121
Gallbladder Neoplasms01971202333.8low041001
Gallstone Disease01964202036.7low1273551120
Gallstones01969201921.4low1511080
Gambling02007200717.0low000100
Gambling, Pathologic02007200717.0low000100
Gangrene01963196361.0low010000
Gastric Dilatation01979200828.0low110200
Gastric Diseases01968201730.9low131120
Gastric Fistula01965200447.5low0404100
Gastric Stasis02000201516.0low001320
Gastric Ulcer01970200343.3low0205100
Gastrin-Producing Tumor01994201619.0low001010
Gastrinoma01994201619.0low001010
Gastritis01964201341.4low1145110
Gastritis, Atrophic01985200929.0low011100
Gastroduodenal Ulcer01965201047.5low1382100
Gastroenteritis01979197945.0low010000
Gastroesophageal Reflux01972202128.7low674721
Gastrointestinal Stromal Neoplasm02012201212.0low000010
Gastrointestinal Stromal Tumors02012201212.0low000010
Gastroparesis02000201516.0low001320
Genetic Predisposition02001202114.1low000551
Germinoblastoma01994199430.0low001000
Giant Cell Arteritis01999199925.0low001000
Giardia duodenalis Infection01973201628.0low020210
Giardiasis01973201628.0low020210
Glial Cell Tumors01994200825.8low003100
Glioblastoma01996201419.8low001210
Glioma01994200825.8low003100
Glomus Jugulare Tumor01989198935.0low010000
Glucose Intolerance01998201613.2low001040
Glucose Metabolic Disorder02014201410.0low000010
Glycosuria01981198143.0low010000
Graft vs Host Disease0202020204.0low000010
Graft-Versus-Host Disease0202020204.0low000010
Gram-Negative Bacterial Infections01997199727.0low001000
Granulocytic Leukemia, Chronic0201520159.0low000010
Growth Disorders01994199430.0low001000
Hakim Syndrome01988199731.5low011000
Hallucination of Body Sensation02003201118.0low000210
Hallucinations02003201118.0low000210
Headache01969199343.0low011000
Headache, Tension01994199430.0low101000
Heart Failure0201520196.8low000040
Helicobacter Infections01994201721.8low308540
Helminthiasis, Animal02003200321.0low000100
Hemochromatosis01963198652.6low090000
Hemolysis01984198440.0low010000
Hemorrhage01986200629.4low033200
Hemorrhage, Peptic Ulcer01989199034.5low011000
Hemorrhage, Subarachnoid01989198935.0low010000
Hemorrhagic Proctocolitis01995199529.0low001000
Hemorrhagic Shock01986201027.0low011100
Hemosiderosis01964198649.0low020000
Hepatic Encephalopathy01983199236.0low022000
Hepatic Failure01997199727.0low001000
Hepatic Porphyria01995199529.0low001000
Hepatitis01965198648.2low1130000
Hepatitis A01966197255.8low050000
Hepatitis B01975197549.0low010000
Hepatitis B Virus Infection01975197549.0low010000
Hepatitis, Chronic02003200321.0low000200
Hepatitis, Infectious01966197255.8low050000
Hepatitis, Viral, Human01988198836.0low010000
Hepatocellular Carcinoma0202120232.0low000002
Hepatolenticular Degeneration01978198841.0low020000
Hernia, Inguinal01975197549.0low010000
Heroin Abuse01985198539.0low010000
Heroin Dependence01985198539.0low010000
Human Trichinellosis01979200625.8low010300
Huntington Disease01980199240.3low081000
Hydrocephalus, Normal Pressure01988199731.5low011000
Hydrosyringomyelia01974197450.0low010000
Hyperactivity, Motor02001202312.0low000101
Hyperandrogenism02012201212.0low000010
Hypercalcemia01972198646.9low1110000
Hypercholesterolemia02002202115.5low000411
Hyperemesis Gravidarum0201520226.7low000021
Hyperemia01968200339.8low031100
Hyperglycemia01967202231.6low8915331
Hyperglycemia, Postprandial01967202231.6low8915331
Hyperinsulinism01967200827.9low425300
Hyperlipemia01967201234.1low240310
Hyperlipidemias01967201234.1low240310
Hypernatremia02009200915.0low000100
Hypernutrition0202020232.5low000011
Hyperparathyroidism01967198249.9low170000
Hyperphagia01983202120.5low1741192
Hyperplasia01973199934.0low0716000
Hypersensitivity01966196956.5low020000
Hypertension01985202116.6low012151
Hypertension, Portal01978198343.0low030000
Hyperthyroid01966198152.7low030000
Hyperthyroidism01966198152.7low030000
Hypertriglyceridemia02003201215.3low200120
Hypertrophy01969202135.1low01314001
Hypocalcemia01968198348.2low160000
Hypoglycemia01969201440.3low1111030
Hypokalemia01968197951.5low040000
Hypomenorrhea01967196757.0low010000
Hyponatremia02009200915.0low000100
Hypoparathyroidism01968198348.5low020000
Hypophosphatemia0202220222.0low000001
Hypotension01986201328.0low020010
Hypothermia01965200431.7low021300
Hypothermia, Accidental01965200431.7low021300
Hypothyroidism01981198939.0low020000
Hypovolemia02001200123.0low000100
Hypovolemic02001200123.0low000100
Hypoxia01977202117.5low211141
Ichthyosis01978197846.0low010000
Icterus01967197751.7low090000
Icterus Gravis Neonatorum01991199730.7low003000
Idiopathic Hypoparathyroidism01968198348.5low020000
Idiopathic Parkinson Disease01982202225.7low484731
Idiopathic Tropical Malabsorption Syndrome01963196560.0low020000
Ileal Diseases02008200816.0low100100
Ileitis01970199840.0low011000
Immunologic Deficiency Syndromes01975197549.0low010000
Impaired Glucose Tolerance01998201613.2low001040
Inadequate Sleep02011201113.0low000010
Inappropriate GH Secretion Syndrome (Acromegaly)01987200132.1low227100
Indigestion01969202020.1low2141150
Infant Malnutrition01970197054.0low010000
Infant, Premature, Diseases01997200225.0low003100
Infant, Small for Gestational Age01997199826.5low002000
Infantile Diarrhea01979198144.0low020000
Infantile Respiratory Distress Syndrome01997199727.0low002000
Infection02000201218.0low001010
Infections02000201218.0low001010
Infections, Helicobacter01994201721.8low308540
Infections, Nematode01985198539.0low010000
Infections, Salmonella01976197946.5low020000
Infections, Staphylococcal02014201410.0low000010
Infectious Bovine Rhinotracheitis01999199925.0low001000
Inflammation01993202214.0low1039142
Inflammatory Bowel Diseases01995200822.5low002200
Inguinal Hernia01975197549.0low010000
Injuries02002200222.0low000100
Injuries, Spinal Cord01994201121.6low002410
Injury, Ischemia-Reperfusion02000201715.5low001210
Injury, Myocardial Reperfusion0202020204.0low000010
Innate Inflammatory Response01993202214.0low1039142
Insulin Resistance01970202214.0low2118113
Insulin Sensitivity01970202214.0low2118113
Insulinoma01983201228.4low023110
Intestinal Diseases01965202038.0low080220
Intestinal Diseases, Parasitic01981200332.0low010100
Intestinal Neoplasms01978201628.4low027010
Intestinal Obstruction01967198944.2low180000
Intestinal Polyps01970197054.0low010000
Intestinal Pseudo-Obstruction01982201526.8low020110
Intraocular Pressure01990199332.5low002000
Invasiveness, Neoplasm01999201418.0low001110
Irritable Bowel Syndrome02006202312.4low200852
Ischemia01967202132.5low153011
Ischemic Attack, Transient01990199034.0low001000
Island Cell Tumor01968199742.5low0165000
Itching02011201113.0low000010
Jaundice01967197751.7low090000
Jaundice, Cholestatic02010201014.0low000100
Jaundice, Neonatal01991199730.7low003000
Jaundice, Obstructive02010201014.0low000100
Kidney Diseases01970201734.4low130110
Kidney Failure, Chronic01970200445.2low0110100
Kidney Neoplasms01999201517.0low001010
Kwashiorkor01968196856.0low010000
Labhart-Willi Syndrome01989200726.8low012100
Labor, Premature01995199529.0low001000
Lactic Acidosis0201620168.0low000010
Lactose Intolerance01975198444.5low020000
Lassitude01997199727.0low001000
Leanness01998202311.6low501061
Leiomyoma02012201212.0low000010
Leiomyosarcoma01999201218.5low001010
Leiomyosarcoma, Epithelioid01999201218.5low001010
Lesch-Nyhan Syndrome01983198341.0low010000
Lesion of Sciatic Nerve02005202113.2low000301
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0201520159.0low000010
Lipid Metabolism, Inborn Error01980198044.0low010000
Lipomatosis01973197351.0low010000
Liver Cirrhosis01963202248.5low1382001
Liver Cirrhosis, Alcoholic01978199740.1low061000
Liver Cirrhosis, Biliary01973199739.8low022000
Liver Diseases01964201444.5low0262110
Liver Diseases, Alcoholic01981199038.5low011000
Liver Dysfunction01964201444.5low0262110
Liver Failure01997199727.0low001000
Liver Failure, Acute01996199628.0low001000
Liver Neoplasms01968202325.6low053132
Liver Steatosis01967201335.0low042020
Local Neoplasm Recurrence0202120213.0low000001
Long Sleeper Syndrome01969196955.0low010000
Lordosis02002200222.0low000100
Lung Diseases02008200816.0low000100
Lung Neoplasms01989202226.6low037111
Lymph Node Metastasis01999200024.5low002000
Lymphatic Diseases01970197054.0low010000
Lymphoma01994199430.0low001000
Malabsorption Syndromes01964201440.3low1171610
Malignant Carcinoid Syndrome01979199537.7low021000
Malignant Melanoma01964201230.3low010110
Malnourishment0201120237.0low000011
Malnutrition0201120237.0low000011
Malocclusion0202220222.0low000001
Marasmus01975200435.3low032100
Medulloblastoma01999199925.0low001000
Megacolon01978199640.2low031000
Melanoma01964201230.3low010110
Memory Disorders02003201317.0low100210
Meningeal Neoplasms02005200519.0low000100
Meningioma02005200519.0low000100
Menopause02000201218.0low001010
Mental Disorders01975201833.6low0101120
Mesenteric Vascular Occlusion01963197157.0low020000
Metabolic Diseases02007201115.0low000110
Metabolic Syndrome02007201712.0low100240
Metaplasia01984198440.0low010000
Metastase01968201432.2low021010
Migraine Disorders01984202023.9low030220
Milk Hypersensitivity02006200618.0low000100
Milk-Alkali Syndrome01972198646.9low1110000
Miosis01990199034.0low001000
MODS0201920195.0low000010
Mononeuritis02001200123.0low000100
Mononeuropathies02001200123.0low000100
Mood Disorders01989201818.8low010120
Morbid Obesity01988201619.3low233770
Morphine Abuse01987200628.5low027200
Morphine Dependence01987200628.5low027200
Movement Disorders01975197549.0low010000
MPTP Neurotoxicity Syndrome01990199034.0low001000
Mucositis, Oral01978197846.0low010000
Multiple Endocrine Neoplasia Type 101996199628.0low001000
Multiple Organ Failure0201920195.0low000010
Muscle Contraction01966202236.3low1423213234122
Muscle Cramp01974197450.0low010000
Muscle Relaxation01977201828.6low21113830
Muscle Spasm01970197651.7low030000
Muscle Tissue Neoplasms01989198935.0low010000
Muscular Atrophy01989198935.0low010000
Myocardial Infarction0201720205.3low000030
Myotonic Dystrophy01962196262.0low010000
Nausea01971201824.5low853830
Necrosis01973202122.8low044441
Necrotizing Enterocolitis02002200222.0low000100
Nelson Syndrome01987198737.0low010000
Neoplasm Metastasis01968201432.2low021010
Neoplasms01973202025.7low088780
Neoplasms, Bronchial01979197945.0low010000
Neoplasms, Nerve Tissue01992199232.0low001000
Neoplasms, Nervous System01990199233.0low003000
Neoplasms, Skull01989198935.0low010000
Nephrosis01964196460.0low010000
Nerve Degeneration01983202127.9low035201
Nerve Pain01992201818.2low002220
Nervous System Diseases01981198839.8low060000
Nervous System Disorders01981198839.8low060000
Neuralgia01992201818.2low002220
Neuralgia, Sciatic0201620168.0low000010
Neuritis02014201410.0low000010
Neuroblastoma01989201628.8low0210110
Neurodegenerative Diseases0201520225.5low000011
Neuroectodermal Tumors, Primitive01999199925.0low001000
Neuroectodermal Tumors, Primitive, Peripheral01989199432.5low015000
Neuroendocrine Tumors01994201621.9low006220
Neuronal Ceroid-Lipofuscinoses02002200222.0low000100
Neuroretinitis01970197054.0low010000
Neuroses02004200420.0low000100
Neurotic Disorders02004200420.0low000100
Nicotine Addiction02001200322.0low000200
Niemann-Pick Disease02004200420.0low000100
Niemann-Pick Diseases02004200420.0low000100
Nociceptive Pain0202220222.0low000001
Non-alcoholic Fatty Liver Disease0201220227.0low100022
Nutrition Disorders01972200337.8low132100
Nutritional Disorders01972200337.8low132100
Obesity01969202319.1low364939689319
Obesity, Morbid01988201619.3low233770
Obsessive-Compulsive Disorder02004200420.0low000100
Ophthalmoplegia, Progressive Supranuclear01987198737.0low010000
Opioid-Related Disorders01984198440.0low010000
Osteogenic Sarcoma0201820186.0low000010
Osteoporosis02006201314.5low000110
Osteosarcoma0201820186.0low000010
Ostertagiasis02002200222.0low000100
Ovarian Cysts01970197054.0low010000
Ovarian Neoplasms01981199733.7low012000
Overweight02007202111.6low11008101
Ovine Diseases01981198143.0low010000
Pain01969202331.5low654282771
Pain, Chronic0202220222.0low000001
Pain, Postoperative01989199731.3low212000
Palmoplantaris Pustulosis01978202018.3low010020
Pancreatic Cyst01963198051.5low0110000
Pancreatic Diseases01960200948.5low222312300
Pancreatic Fistula01963200447.4low0414100
Pancreatic Insufficiency01980202032.7low42417310
Pancreatic Neoplasms01960202138.9low61467518101
Pancreatic Pseudocyst01985200032.2low023000
Pancreatitis01960202239.2low535510757165
Pancreatitis, Chronic01960202131.6low170731
Panic Attacks01992202122.5low80241851
Panic Disorder01992202122.5low80241851
Paraganglioma01979198343.0low020000
Paraganglioma, Gangliocytic01979198343.0low020000
Paraneoplastic Syndromes01989198935.0low010000
Parathyroid Neoplasms01973197649.5low020000
Parkinson Disease01982202225.7low484731
Parkinson Disease, Secondary01986199135.0low012000
Parkinsonian Disorders0201520216.0low000011
Parotiditis01972197252.0low010000
Peptic Ulcer01965201047.5low1382100
Peptic Ulcer Perforation01980198044.0low010000
Peripheral Nerve Diseases01983201123.4low013410
Peripheral Nerve Injuries0200920219.0low000101
Peripheral Nerve Injury0200920219.0low000101
Peripheral Nervous System Diseases01983201123.4low013410
Peritoneal Carcinomatosis02011201113.0low000010
Peritoneal Neoplasms02011201113.0low000010
Pernicious Vomiting of Pregnancy0201520226.7low000021
Pheochromocytoma01976198941.5low020000
Pheochromocytoma, Extra-Adrenal01976198941.5low020000
Phlegmon01996199628.0low001000
Phobic Disorders01994199927.0low003000
Pituitary Neoplasms01979201431.2low064210
Plasma Cell Tumor01964196460.0low010000
Plasmacytoma01964196460.0low010000
Pneumoretroperitoneum01968196856.0low010000
Poisoning02004200420.0low100100
Polyarthritis01985200725.3low010200
Polycystic Ovarian Syndrome02004201414.3low000330
Polycystic Ovary Syndrome02004201414.3low000330
Polyneuropathies02001200123.0low000100
Polyneuropathy, Acquired02001200123.0low000100
Polyploid01982198242.0low010000
Porphyrias, Hepatic01995199529.0low001000
Post-Cholecystectomy Syndrome01995201023.6low003200
Postgastrectomy Syndromes01963199645.2low072000
Postoperative Complications01964201736.9low51811320
Prader-Willi Syndrome01989200726.8low012100
Precancerous Conditions01978201431.3low035010
Prediabetes01970201824.3low110020
Prediabetic State01970201824.3low110020
Pregnancy01970202229.3low0292511102
Pregnancy, Ectopic01970197054.0low010000
Premature Birth02006200618.0low000100
Premenstrual Syndrome02001200421.5low100200
Premenstrual Tension02001200421.5low100200
Preterm Birth02006200618.0low000100
Proctocolitis01995199529.0low001000
Prostatic Hyperplasia01993199331.0low001000
Prostatic Neoplasms0201620168.0low000010
Protein-Energy Malnutrition01975200435.3low032100
Protein-Losing Enteropathies01968196955.5low020000
Proteinuria02007200717.0low000100
Pruritus02011201113.0low000010
Psoriasis01978202018.3low010020
Psychophysiologic Disorders01970201632.2low021110
Psychoses01984201622.0low021310
Psychoses, Drug01994199430.0low001000
Psychotic Disorders01984201622.0low021310
Ptosis, Eyelid01980198542.0low050000
Pulmonary Fibrosis01971197153.0low010000
Pyloric Stenosis01976197946.5low020000
Pyrexia01994200723.1low004400
Recrudescence01970201239.2low1138110
Rectal Neoplasms01977199538.7low021000
Remission, Spontaneous01982199237.0low011000
Renal Artery Obstruction01974197450.0low010000
Renal Artery Stenosis01974197450.0low010000
Reperfusion Injury02000201715.5low001210
Respiration Disorders01990201720.5low001010
Respiratory Distress Syndrome, Newborn01997199727.0low002000
Respiratory Insufficiency02000200024.0low001000
Retinitis01970197054.0low010000
Rhabdomyosarcoma01999199925.0low001000
Rheumatic Diseases02011201113.0low000010
Rheumatism02011201113.0low000010
Rheumatoid Arthritis01964196460.0low010000
Salivary Gland Diseases01970197054.0low010000
Salivary Gland Fistula01970197054.0low010000
Sarcoma01973197351.0low010000
Sarcoma, Epithelioid01973197351.0low010000
Sarcoma, Ewing02004201316.0low000210
Sarcoma, Small Cell01994199430.0low001000
Sarcopenia0202220222.0low000001
Schizophrenia01981202132.9low113615541
Sciatica0201620168.0low000010
Scleroderma, Systemic01966200535.8low032100
Sclerosis01973199639.5low011000
Sclerosis, Systemic01966200535.8low032100
Seizures01980202330.3low01110211
Sensitivity and Specificity01991202024.2low80251410
Sepsis02003201415.5low000110
Shock01986199534.0low021000
Shock, Septic01986201723.4low022120
Short Bowel Syndrome02001200720.0low000200
Siamese Twins01991199133.0low001000
Skin Diseases01982198242.0low010000
Sleep Apnea, Obstructive02008200816.0low000100
Sleep Initiation and Maintenance Disorders0202320231.0low000001
Sleep Wake Disorders01969196955.0low010000
Small Cell Lung Carcinoma0202020204.0low000010
Smoking Cessation02007200717.0low100100
Somatostatinoma01994199629.0low002000
Spasm01970197651.7low030000
Sphincter of Oddi Dysfunction02007201412.2low000130
Spinal Cord Injuries01994201121.6low002410
Spinocerebellar Ataxias0201620234.0low000012
Splenic Diseases02007200717.0low000100
Staphylococcal Infections02014201410.0low000010
Starvation01972202232.3low0103312
Status Epilepticus02007202310.2low000211
Steatorrhea01973201530.0low010010
Stomach Neoplasms01972201931.0low0147250
Stomach Ulcer01970200343.3low0205100
Stomatitis01978197846.0low010000
Stress Disorders, Post-Traumatic01999201514.7low001020
Stroke0200120238.0low000112
Stunted Growth01994199430.0low001000
Subarachnoid Hemorrhage01989198935.0low010000
Substance Withdrawal Syndrome01990201025.7low00181000
Substance-Related Disorders01983202024.1low013310
Suicidal Ideation0201820186.0low000010
Supranuclear Palsy, Progressive01987198737.0low010000
Swine Diseases01990199034.0low001000
Symptom Cluster01973198546.4low0120000
Syndrome01973198546.4low0120000
Taste Disorder, Anterior Tongue01978201627.0low010010
Tension-Type Headache01994199430.0low101000
Teratocarcinoma02002200222.0low000100
Thoracic Neoplasms01994199430.0low001000
Thymus Neoplasms02001200123.0low000100
Thyroid Diseases01987198737.0low010000
Thyroid Neoplasms01975202029.9low069230
Tobacco Use Disorder02001200322.0low000200
Tremor01983198540.0low020000
Trichinellosis01979200625.8low010300
Trichostrongyloidiasis01981198143.0low010000
Trichostrongylosis01981198143.0low010000
Typhoid Fever01964196460.0low020000
Ulcer02006200618.0low000100
Uremia01974197450.0low010000
Urinary Incontinence01990199034.0low001000
Uterine Neoplasms01984198440.0low010000
Vibrio cholerae Infection01967197553.3low030000
Viral Hepatitis, Human01988198836.0low010000
Visceral Pain02013201311.0low000010
Vomiting01968201427.9low033230
Vulvar Neoplasms01983198341.0low010000
Weight Gain01989202018.2low31714140
Weight Loss01993202314.4low110916243
Weight Reduction01993202314.4low110916243
Wounds and Injuries02002200222.0low000100
Xeroderma01978197846.0low010000
Zollinger-Ellison Syndrome01968201346.8low0392010

Safety/Toxicity (12)

ArticleYear
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Clinical pharmacology and therapeutics, , Volume: 112, Issue:6
2022
Cholecystokinin-8 inhibits methamphetamine-induced neurotoxicity via an anti-oxidative stress pathway.
Neurotoxicology, , Volume: 57
2016
Laparoscopic cholecystectomy for treatment of biliary dyskinesia is safe and effective in the pediatric population.
The American surgeon, , Volume: 74, Issue:11
2008
Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 69, Issue:1
2002
Linkage of oxidative and nonoxidative ethanol metabolism in the pancreas and toxicity of nonoxidative ethanol metabolites for pancreatic acinar cells.
Surgery, , Volume: 129, Issue:6
2001
Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.
Cancer chemotherapy and pharmacology, , Volume: 34, Issue:6
1994
[Glutamate neurotoxicity and neuroprotective factors].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 103, Issue:5
1994
In vivo modulation of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in human pancreatic cancer xenografts.
Anticancer research, , Volume: 14, Issue:6B
Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity.
Brain research, , Aug-23, Volume: 557, Issue:1-2
1991
Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.
Science (New York, N.Y.), , May-08, Volume: 256, Issue:5058
1992
Mechanisms of cholecystokinin-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity.
Brain research, , Oct-02, Volume: 592, Issue:1-2
1992
[A 13-week subacute oral toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate dimethanesulfonate (FUT-187) in dogs.
The Journal of toxicological sciences, , Volume: 17 Suppl 4
1992

Long-term Use (55)

ArticleYear
The critical role of CCK in the regulation of food intake and diet-induced obesity.
Peptides, , Volume: 138
2021
Motility Patterns Following Esophageal Pharmacologic Provocation With Amyl Nitrite or Cholecystokinin During High-Resolution Manometry Distinguish Idiopathic vs Opioid-Induced Type 3 Achalasia.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, , Volume: 18, Issue:4
2020
[The effect of formalin-induced pain on CCK in rat spinal cord neurons].
Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 25, Issue:2
2009
Peripherally injected cholecystokinin-induced neuronal activation is modified by dietary composition in mice.
NeuroImage, , May-01, Volume: 50, Issue:4
2010
Lack of tolerance development with long-term administration of PEGylated cholecystokinin.
Peptides, , Volume: 30, Issue:4
2009
Involvement of endogenous cholecystokinin in tolerance to morphine antinociception in the nucleus accumbens of rats.
Behavioural brain research, , Oct-02, Volume: 173, Issue:1
2006
Pancreatic exocrine response to long-term high-fat diets in rats.
JOP : Journal of the pancreas, , Jul-10, Volume: 7, Issue:4
2006
Lack of trophic pancreatic effects in humans with long-term administration of ximelagatran.
Pancreas, , Volume: 32, Issue:2
2006
Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain.
Brain research, , Dec-29, Volume: 887, Issue:2
2000
Estradiol alters cholecystokinin stimulus-response coupling in rat pancreatic acini.
The American journal of physiology, , Volume: 275, Issue:5
1998
Inhibition of gastric emptying and intestinal transit by amphetamine through a mechanism involving an increased secretion of CCK in male rats.
British journal of pharmacology, , Volume: 124, Issue:6
1998
Different actions of CCK on pancreatic and gastric growth in the rat: effect of CCK(A) receptor blockade.
British journal of pharmacology, , Volume: 124, Issue:3
1998
Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats.
Neuroscience letters, , Mar-06, Volume: 244, Issue:1
1998
Specific adaptation of gastric emptying to diets with differing protein content in the rat: is endogenous cholecystokinin implicated?
Gut, , Volume: 41, Issue:5
1997
Long-term blockade of cholecystokinin (CCK): effects of L 364,718 (a CCK receptor antagonist) on pancreatic enzyme storage and secretion.
Pancreas, , Volume: 15, Issue:3
1997
Opioid and anti-opioid peptides.
Fundamental & clinical pharmacology, , Volume: 9, Issue:5
1995
The role of nitroglycerin preparations in the treatment of post-acute and chronic pancreatitis.
Therapia Hungarica (English edition), , Volume: 41, Issue:2
1993
Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine.
Brain research, , Oct-15, Volume: 625, Issue:1
1993
Cholecystokinin gene expression in rat amygdaloid neurons: normal distribution and effect of morphine tolerance.
Brain research. Molecular brain research, , Volume: 21, Issue:3-4
1994
The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.
Neuroreport, , Nov-18, Volume: 5, Issue:2
1993
Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.
Pancreas, , Volume: 9, Issue:5
1994
Cholecystokinin modulates isoproterenol induced changes in rat parotid gland.
Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology, , Volume: 106, Issue:1
1993
Cholecystokinin and enkephalin levels following ethanol administration in rats.
Peptides, ,Summer, Volume: 2, Issue:2
1981
Chronic administration of an organophosphorus insecticide to rats alters cholinergic muscarinic receptors in the pancreas.
Chemico-biological interactions, , Volume: 48, Issue:3
1984
Effect of cholecystokinin-octapeptide, caerulein, and pentagastrin on epithelial cell proliferation in the murine gallbladder.
Gastroenterology, , Volume: 83, Issue:2
1982
Modulation of CNS dopamine receptors by peptides.
Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 7, Issue:4-6
1983
Hormonal control of pancreatic growth.
The Journal of clinical investigation, , Volume: 52, Issue:9
1973
[The pancreas and alcohol].
Schweizerische medizinische Wochenschrift, , Jul-20, Volume: 115, Issue:29
1985
Long-term antidepressant treatment reduces neuronal responsiveness to flurazepam: an electrophysiological study in the rat.
Neuroscience letters, , Jan-27, Volume: 73, Issue:3
1987
Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion.
European journal of clinical investigation, , Volume: 18, Issue:5
1988
Dopamine, GABA, cholecystokinin and opioids in neuroleptic-induced tardive dyskinesia.
Neuroscience and biobehavioral reviews, , Volume: 12, Issue:3-4
Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat.
Brain research, , Feb-20, Volume: 480, Issue:1-2
1989
Role of cholecystokinin in the control of food intake.
Gastroenterology clinics of North America, , Volume: 18, Issue:4
1989
Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists.
Psychopharmacology, , Volume: 98, Issue:3
1989
CCK-antagonist L-364,718: influence on rat pancreatic growth induced by caerulein and bombesin-like peptides.
Regulatory peptides, , Volume: 24, Issue:1
1989
Endogenous cholecystokinin regulates growth of human cholangiocarcinoma.
Annals of surgery, , Volume: 210, Issue:3
1989
Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice.
Gut, , Volume: 28 Suppl
1987
Small bowel bypass prevents the trophic action of cholecystokinin on the rat pancreas.
International journal of pancreatology : official journal of the International Association of Pancreatology, , Volume: 2, Issue:4
1987
Trophic effect of bombesin on the rat pancreas: is it mediated by the release of gastrin or cholecystokinin?
Peptides, , Volume: 6 Suppl 3
1985
Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment.
Brain research, , May-21, Volume: 516, Issue:2
1990
Effects of long-term CCK stimulation and CCK blockade on pancreatic and intestinal growth, morphology, and function.
Digestion, , Volume: 46 Suppl 2
1990
Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
The Journal of neuroscience : the official journal of the Society for Neuroscience, , Volume: 10, Issue:2
1990
Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
The American journal of physiology, , Volume: 260, Issue:2 Pt 1
1991
In-vitro effect of pirenzepine on motility of canine gall-bladder.
The Journal of pharmacy and pharmacology, , Volume: 42, Issue:2
1990
Role of cholecystokinin in cholestyramine-induced changes of the exocrine pancreas.
Pancreas, , Volume: 6, Issue:5
1991
Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
European journal of pharmacology, , Sep-24, Volume: 202, Issue:3
1991
Effect of lorglumide (CR-1409) on pancreatic secretory and trophic response to caerulein in newborn rats.
Acta physiologica Hungarica, , Volume: 78, Issue:1
1991
Aging and the trophic effects of cholecystokinin, bombesin and pentagastrin on the rat pancreas.
Pancreas, , Volume: 6, Issue:4
1991
Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity.
European journal of pharmacology, , Dec-10, Volume: 209, Issue:1-2
1991
Direct effect of bombesin on pancreatic and gastric growth in suckling rats.
Regulatory peptides, , Sep-22, Volume: 41, Issue:2
1992
Effect of acute and chronic administration of ethanol on the pancreatic exocrine response to cholecystokinin in rats fed different diets.
Clinical science (London, England : 1979), , Volume: 82, Issue:4
1992
Effect of hormones on pancreatic macromolecular transport.
Gastroenterology, , Volume: 68, Issue:6
1975
Effects on exocrine and endocrine rat pancreas of long-term administration of CCK-PZ (cholecystokinin-pancreozymin) or synthetic octapeptide - CCK-PZ.
Scandinavian journal of gastroenterology, , Volume: 11, Issue:5
1976
Effect of acute and chronic administration of 5-FU on pancreatic secretion.
The American journal of gastroenterology, , Volume: 70, Issue:1
1978
Chronic and acute studies indicating absence of exocrine pancreatic feedback inhibition in dogs.
Digestion, , Volume: 15, Issue:6
1977

Pharmacokinetics (32)

ArticleYear
Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes.
Molecular pharmaceutics, , 06-04, Volume: 15, Issue:6
2018
The role of a pre-load beverage on gastric volume and food intake: comparison between non-caloric carbonated and non-carbonated beverage.
Nutrition journal, , Oct-14, Volume: 10
2011
Biodistribution and pharmacokinetics of PEG-10kDa-cholecystokinin-10 in rats after different routes of administration.
Current drug delivery, , Volume: 7, Issue:2
2010
Wiring and volume transmission in rat amygdala. Implications for fear and anxiety.
Neurochemical research, , Volume: 33, Issue:8
2008
Pioglitazone increases gallbladder volume in insulin-resistant obese mice.
The Journal of surgical research, , Volume: 136, Issue:2
2006
Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 33, Issue:6
2003
A solubilized cellulose fiber decreases peak postprandial cholecystokinin concentrations after a liquid mixed meal in hypercholesterolemic men and women.
The Journal of nutrition, , Volume: 133, Issue:7
2003
Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test.
The American journal of gastroenterology, , Volume: 97, Issue:6
2002
[The effect of bile secretion on the pharmacokinetics of a theophylline sustained-release preparation].
Arzneimittel-Forschung, , Volume: 48, Issue:5A
1998
Fasting gall bladder volume and lithogenicity in relation to glucose tolerance, total and intra-abdominal fat masses in obese non-diabetic subjects.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, , Volume: 22, Issue:4
1998
Cell volume changes modulate cholecystokinin- and carbachol-stimulated amylase release in isolated rat pancreatic acini.
Gastroenterology, , Volume: 113, Issue:5
1997
Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation.
Arzneimittel-Forschung, , Volume: 46, Issue:12
1996
Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs.
Gastroenterology, , Volume: 105, Issue:6
1993
Correlation between gall bladder fasting volume and postprandial emptying in patients with gall stones and healthy controls.
Gut, , Volume: 34, Issue:10
1993
[Effect of a low-fat diet on the fasting volume and postprandial emptying of the gallbladder].
Gastroenterologie clinique et biologique, , Volume: 17, Issue:6-7
1993
Normal fasting volume and postprandial emptying of the denervated donor gallbladder in liver transplant recipients.
Gastroenterology, , Volume: 107, Issue:3
1994
Plasma cholecystokinin levels and gallbladder volumes after proctocolectomy with ileal pouch-anal anastomosis.
Surgery, , Volume: 117, Issue:6
1995
[Significance of the correction of aspirated volumes for the results of the secretin-pancreozymin test (author's transl)].
Zeitschrift fur Gastroenterologie, , Volume: 18, Issue:9
1980
The kinetics of pancreatic amylase secretion and its relationship to volume flow and electrical conductance in the anaesthetized cat.
The Journal of physiology, , Volume: 239, Issue:3
1974
Comparison of effects of ingested medium- and long-chain triglyceride on gallbladder volume and release of cholecystokinin and other gut peptides.
Digestive diseases and sciences, , Volume: 32, Issue:5
1987
[Secretin-pancreozymin test with volume correction in the functional diagnosis of pancreatobiliary secretion].
Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten, , Volume: 47, Issue:5
1987
Gallbladder pressure, compliance, and hysteresis during cyclic volume change.
Canadian journal of physiology and pharmacology, , Volume: 65, Issue:10
1987
Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.
Arzneimittel-Forschung, , Volume: 38, Issue:5
1988
Release of hypothalamic cholecystokinin in cats: effects of nutrient and volume loading.
The American journal of physiology, , Volume: 256, Issue:1 Pt 2
1989
The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man.
European journal of pharmacology, , Jul-18, Volume: 166, Issue:2
1989
Pharmacokinetics and organ catabolism of cholecystokinin octapeptide in pigs.
Regulatory peptides, , Volume: 26, Issue:3
1989
Pharmacokinetics and tolerance of repeated oral doses of loxiglumide.
Arzneimittel-Forschung, , Volume: 39, Issue:11
1989
Volume and enzyme kinetics of human pancreatic secretion after endogenous stimulation with the Lundh test meal.
International journal of pancreatology : official journal of the International Association of Pancreatology, , Volume: 6, Issue:4
1990
Fasting gallbladder volume, postprandial emptying and cholecystokinin release in gallstone patients and normal subjects.
Journal of hepatology, , Volume: 14, Issue:2-3
1992
Effect of loxiglumide and atropine on erythromycin-induced reduction in gallbladder volume in human subjects.
Hepatology (Baltimore, Md.), , Volume: 16, Issue:4
1992
Gallbladder pressure-volume response to gastrointestinal hormones.
The American journal of physiology, , Volume: 230, Issue:6
1976
[The influence of extracellular calcium on volume, enzyme and calcium secretion in the isolated perfused canine pancreas (author's transl)].
Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, , Jan-28, Volume: 169, Issue:3
1977

Bioavailability (23)

ArticleYear
Study of the gastrointestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], , Volume: 20, Issue:6
2020
Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy.
Gastroenterology, , Volume: 156, Issue:6
2019
Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., , Volume: 59, Issue:3
2015
Effects of various food ingredients on gall bladder emptying.
European journal of clinical nutrition, , Volume: 67, Issue:11
2013
Amphiphilic CCK peptides assembled in supramolecular aggregates: structural investigations and in vitro studies.
Molecular bioSystems, , Volume: 7, Issue:3
2011
Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 33, Issue:6
2003
The cyclotides: novel macrocyclic peptides as scaffolds in drug design.
Current opinion in drug discovery & development, , Volume: 5, Issue:2
2002
The effects of intestinal infusion of long-chain fatty acids on food intake in humans.
Gastroenterology, , Volume: 119, Issue:4
2000
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
Journal of medicinal chemistry, , Mar-26, Volume: 41, Issue:7
1998
Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.
International journal of pancreatology : official journal of the International Association of Pancreatology, , Volume: 13, Issue:2
1993
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
Journal of medicinal chemistry, , Jan-08, Volume: 36, Issue:1
1993
Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats.
Digestive diseases and sciences, , Volume: 39, Issue:6
1994
Mechanism of optical isomerization of (S)-N-[1-(2-fluorophenyl)-3,4,6,7- tetrahydro-4-oxopyrrolo[3,2,1-jk] [1,4]-benzodiazepine-3-yl]-1H- indole-2-carboxamide (FK480) in soft capsules containing polyethylene glycol 400 and glycerol.
Pharmaceutical research, , Volume: 11, Issue:12
1994
Correlation between bile acid malabsorption and pancreatic exocrine dysfunction in patients with chronic pancreatitis.
Pancreas, , Volume: 9, Issue:5
1994
Regulation of pancreatic and gallbladder function by absorption of intrajejunal phenylalanine in man.
Klinische Wochenschrift, , Mar-17, Volume: 58, Issue:6
1980
The gallbladder emptying response to sequential exogenous and endogenous cholecystokinin.
Nuclear medicine communications, , Volume: 5, Issue:1
1984
Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.
Arzneimittel-Forschung, , Volume: 38, Issue:5
1988
Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Proceedings of the National Academy of Sciences of the United States of America, , Volume: 83, Issue:13
1986
[Regulation of acinar cell receptors of the pancreas by peptides].
Klinische Wochenschrift, , Jun-02, Volume: 64, Issue:11
1986
Development of CCK-B antagonists.
Neuropeptides, , Volume: 19 Suppl
1991
Potent and sustained satiety actions of a cholecystokinin octapeptide analogue.
The American journal of clinical nutrition, , Volume: 55, Issue:1 Suppl
1992
[Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents].
Therapie, , Volume: 47, Issue:6
1992
Pancreatic cholera. Sudies on tumoral secretions and pathophysiology of diarrhea.
Gastroenterology, , Volume: 69, Issue:1
1975

Dosage (223)

ArticleYear
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Clinical pharmacology and therapeutics, , Volume: 112, Issue:6
2022
Leptin receptor-expressing cells in the ventromedial nucleus of the hypothalamus contribute to enhanced CCK-induced satiety following central leptin injection.
American journal of physiology. Endocrinology and metabolism, , 09-01, Volume: 323, Issue:3
2022
Cholecystokinin-1 receptor agonist induced pathological findings in the exocrine pancreas of non-human primates.
Toxicology and applied pharmacology, , 07-15, Volume: 399
2020
Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen Minipigs.
International journal of obesity (2005), , Volume: 44, Issue:2
2020
Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
Journal of clinical pharmacology, , Volume: 57, Issue:10
2017
Role of guar fiber in appetite control.
Physiology & behavior, , 10-01, Volume: 164, Issue:Pt A
2016
Supplementation with a new trypsin inhibitor from peanut is associated with reduced fasting glucose, weight control, and increased plasma CCK secretion in an animal model.
Journal of enzyme inhibition and medicinal chemistry, , Volume: 31, Issue:6
2016
Effects of various food ingredients on gall bladder emptying.
European journal of clinical nutrition, , Volume: 67, Issue:11
2013
Overnight food deprivation markedly attenuates hindbrain noradrenergic, glucagon-like peptide-1, and hypothalamic neural responses to exogenous cholecystokinin in male rats.
Physiology & behavior, , Sep-10, Volume: 121
2013
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Endocrine, , Volume: 42, Issue:2
2012
Use of satiety peptides in assessing the satiating capacity of foods.
Physiology & behavior, , Jan-18, Volume: 105, Issue:2
2012
The short term satiety peptide cholecystokinin reduces meal size and prolongs intermeal interval.
Peptides, , Volume: 32, Issue:6
2011
Effect of feeding fat or intrajugular infusion of glucagon-like peptide-1 and cholecystokinin on dry matter intake, digestibility, and digesta rate of passage in growing wethers.
Journal of animal science, , Volume: 89, Issue:1
2011
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.
Behavioural brain research, , Mar-01, Volume: 217, Issue:2
2011
Bench-to-bedside review: the gut as an endocrine organ in the critically ill.
Critical care (London, England), , Volume: 14, Issue:5
2010
Protein kinase C delta-mediated processes in cholecystokinin-8-stimulated pancreatic acini.
Pancreas, , Volume: 38, Issue:8
2009
Dose-response effects of PEGylated cholecystokinin on the behavioral satiety sequence.
Physiology & behavior, , Aug-04, Volume: 98, Issue:1-2
2009
The CCK(2) agonist BC-264 decreases predatory fear freezing at high but not low dosages in PVG hooded rats during initial exposure to a cat.
Peptides, , Volume: 30, Issue:4
2009
Effects of active immunization against cholecystokinin 8 on performance, contents of serum hormones, and expressions of CCK gene and CCK receptor gene in pigs.
Endocrine, , Volume: 32, Issue:3
2007
Effect of meta-chlorophenylpiperazine and cholecystokinin on food intake of Osborne-Mendel and S5B/P1 rats.
Obesity (Silver Spring, Md.), , Volume: 15, Issue:3
2007
Dose-response for inhibition by amylin of cholecystokinin-stimulated secretion of amylase and lipase in rats.
Regulatory peptides, , Aug-15, Volume: 130, Issue:1-2
2005
Involvement of the cannabinoid CB1 receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response.
Neurotoxicology, , Volume: 26, Issue:5
2005
Dry matter intake is decreased more by abomasal infusion of unsaturated free fatty acids than by unsaturated triglycerides.
Journal of dairy science, , Volume: 88, Issue:2
2005
Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.
The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jan-12, Volume: 25, Issue:2
2005
Repetitive intranasal administration of cholecystokinin potentiates its central nervous effects.
Physiology & behavior, , Oct-30, Volume: 83, Issue:1
2004
The use of cholecystokinin as an adjunctive treatment for toxin ingestion.
Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1
2004
c-Kit mutant mouse behavioral phenotype: altered meal patterns and CCK sensitivity but normal daily food intake and body weight.
American journal of physiology. Regulatory, integrative and comparative physiology, , Volume: 285, Issue:5
2003
Phosphospecific site tyrosine phosphorylation of p125FAK and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini.
The Journal of biological chemistry, , May-23, Volume: 278, Issue:21
2003
Two effects of high-fat diets on the satiating potency of cholecystokinin-8.
Physiology & behavior, , Volume: 78, Issue:1
2003
Effect of intraperitoneal mRNA antisense-oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats: association with pre-experimental stress.
Neuropeptides, , Volume: 36, Issue:5
2002
Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 69, Issue:1
2002
Dose-response relationships of intranasal cholecystokinin and the P300 event-related brain potential.
Pharmacology, biochemistry, and behavior, , Volume: 73, Issue:3
2002
Dominant negative Rab3D inhibits amylase release from mouse pancreatic acini.
The Journal of biological chemistry, , May-17, Volume: 277, Issue:20
2002
Pharmacological characterization of cholecystokinin receptors mediating contraction of human gallbladder and ascending colon.
Regulatory peptides, , Apr-15, Volume: 105, Issue:1
2002
The cholecystokinin analogues JMV-180 and CCK-8 stimulate phospholipase C through the same binding site of CCK(A) receptor in rat pancreatic acini.
British journal of pharmacology, , Volume: 133, Issue:8
2001
Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response.
Peptides, , Volume: 22, Issue:8
2001
The inability of CCK to block (or CCK antagonists to substitute for) the stimulus effects of chlordiazepoxide.
Pharmacology, biochemistry, and behavior, , Volume: 69, Issue:1-2
Effects of lorglumide and atropine on MgSO(4)-induced gallbladder emptying in conscious dogs.
Research in veterinary science, , Volume: 69, Issue:2
2000
Effects of intraluminal trypsin and bile on the exocrine and endocrine pancreas after pancreaticobiliary diversion and biliodigestive shunt.
Pancreas, , Volume: 20, Issue:2
2000
Morphological changes in rat pancreatic slices associated with inhibition of enzyme secretion by high concentrations of secretagogues.
The Journal of cell biology, , Volume: 76, Issue:2
1978
Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 21, Issue:4
1999
Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin.
Japanese journal of pharmacology, , Volume: 79, Issue:2
1999
Antianalgesic action of dynorphin A mediated by spinal cholecystokinin.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), , Volume: 220, Issue:3
1999
Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones.
Digestive diseases and sciences, , Volume: 44, Issue:1
1999
Inhibition of stimulated amylase secretion by adrenomedullin in rat pancreatic acini.
Endocrinology, , Volume: 140, Issue:2
1999
Progression from homologous to heterologous desensitization of contraction in gastric smooth muscle cells.
The Journal of pharmacology and experimental therapeutics, , Volume: 288, Issue:2
1999
The basis for progesterone impairment of gallbladder contractility in male guinea pigs in vitro.
The Journal of surgical research, , Volume: 79, Issue:2
1998
Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF).
Regulatory peptides, , Feb-27, Volume: 73, Issue:3
1998
Plasma cholecystokinin and gallbladder responses to increasing doses of bombesin in celiac disease.
Digestive diseases and sciences, , Volume: 43, Issue:3
1998
Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin.
The Journal of pharmacology and experimental therapeutics, , Volume: 284, Issue:3
1998
The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers.
Gut, , Volume: 41, Issue:6
1997
Cholecystokinin (CCK) regulates somatostatin secretion through both the CCK-A and CCK-B/gastrin receptors in sheep.
The Journal of physiology, , Dec-15, Volume: 505 ( Pt 3)
1997
Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice.
British journal of pharmacology, , Volume: 122, Issue:6
1997
Effect of cholecystokinin and gastrin on human peripheral blood lymphocyte functions, implication of cyclic AMP and interleukin 2.
Regulatory peptides, , Jun-18, Volume: 70, Issue:2-3
1997
Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
British journal of pharmacology, , Volume: 121, Issue:4
1997
Defect in pancreatic exocrine and endocrine response to CCK in genetically diabetic OLETF rats.
The American journal of physiology, , Volume: 270, Issue:4 Pt 1
1996
The effect of pancreatic denervation and atropine on the cholecystokinin-induced pancreatic exocrine response.
Pancreas, , Volume: 12, Issue:1
1996
Intracerebroventricular injection of CCK reduces operant sugar intake in pigs.
Physiology & behavior, , Volume: 60, Issue:1
1996
Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
The Journal of surgical research, , Feb-15, Volume: 61, Issue:1
1996
Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake.
Metabolism: clinical and experimental, , Volume: 45, Issue:1
1996
Chronic oral administration of synthetic trypsin inhibitor camostate reduces amylase release from isolated rat pancreatic acini.
International journal of pancreatology : official journal of the International Association of Pancreatology, , Volume: 18, Issue:2
1995
Effect of neurotensin on pancreatic growth and pancreatic polyamine metabolism in rats.
International journal of pancreatology : official journal of the International Association of Pancreatology, , Volume: 18, Issue:2
1995
Comparison of the satiating potencies of cholecystokinin-33 and cholecystokinin-8.
Pharmacology, biochemistry, and behavior, , Volume: 45, Issue:1
1993
Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors.
The American journal of physiology, , Volume: 264, Issue:4 Pt 1
1993
Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
Synapse (New York, N.Y.), , Volume: 13, Issue:2
1993
Age, as well as cell turnover kinetics, regulates brain/gut repair.
Mechanisms of ageing and development, , Volume: 69, Issue:3
1993
Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease.
Gastroenterology, , Volume: 105, Issue:4
1993
Effects of peptide histidine isoleucine on pancreatic exocrine secretion in anaesthetized dogs.
Clinical and experimental pharmacology & physiology, , Volume: 20, Issue:7-8
Does acetylsalicylic acid interfere with stimulated pancreatic secretion? An experimental study in the rat.
Pancreas, , Volume: 8, Issue:4
1993
Intestinal, pancreatic, and hepatic effects of gastrointestinal hormones in a total parenteral nutrition rat model.
JPEN. Journal of parenteral and enteral nutrition, , Volume: 17, Issue:4
Characterization of cholecystokinin receptors on the human sphincter of Oddi.
Surgery, , Volume: 114, Issue:5
1993
Mechanism of bombesin-induced pancreatic secretion in unanesthetized rats.
Peptides, , Volume: 14, Issue:4
Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice.
The American journal of physiology, , Volume: 265, Issue:3 Pt 2
1993
Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats.
Digestive diseases and sciences, , Volume: 39, Issue:6
1994
Effect of intravenous human gastrin-releasing peptide on food intake in humans.
Gastroenterology, , Volume: 106, Issue:5
1994
Effects of cholecystokinin antagonists on the discriminative stimulus effects of cocaine in rats and monkeys.
Drug and alcohol dependence, , Volume: 34, Issue:2
1994
Cholecystokinin and estradiol synergistically potentiate satiety in rats.
Peptides, , Volume: 15, Issue:5
1994
Cholecystokinin is a physiological regulator of gastric acid secretion in man.
European journal of clinical investigation, , Volume: 24, Issue:6
1994
The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.
Physiology & behavior, , Volume: 54, Issue:4
1993
Mechanism of optical isomerization of (S)-N-[1-(2-fluorophenyl)-3,4,6,7- tetrahydro-4-oxopyrrolo[3,2,1-jk] [1,4]-benzodiazepine-3-yl]-1H- indole-2-carboxamide (FK480) in soft capsules containing polyethylene glycol 400 and glycerol.
Pharmaceutical research, , Volume: 11, Issue:12
1994
Role of nutrient fat and cholecystokinin in regulation of gallbladder emptying in man.
Digestive diseases and sciences, , Volume: 40, Issue:3
1995
Cholecystokinin effect on human lymphocyte ionized calcium and mitogenesis.
The Journal of surgical research, , Volume: 58, Issue:2
1995
Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
Psychopharmacology, , Volume: 114, Issue:3
1994
Preliminary evidence for the enterohepatic circulation of progesterone in the pig.
The British veterinary journal, , Volume: 150, Issue:6
Somatostatin inhibits cholecystokinin-induced pancreatic protein secretion via cholinergic pathways.
Pancreas, , Volume: 10, Issue:4
1995
Effects of cholecystokinin (CCK)-JMV-180 on the CCK receptors of rabbit pancreatic acini and gallbladder smooth muscle.
Japanese journal of pharmacology, , Volume: 67, Issue:3
1995
Supramaximal inhibition of cholecystokinin-induced pancreatic amylase release involves desensitization to cytoplasmic Ca2+.
Scandinavian journal of gastroenterology, , Volume: 29, Issue:6
1994
Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.
Cancer research, , Jul-01, Volume: 54, Issue:13
1994
Novel CCK analogues and bombesin: a detailed analysis between phosphoinositide breakdown and high-dose inhibition of pancreatic enzyme secretion in three rodent species.
The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:2
1994
In vitro release of cholecystokinin octapeptide-like immunoreactivity from rat brain synaptosomes.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Jan-31, Volume: 59, Issue:5
1981
Biological activity of the C-terminal octapeptide of cholecystokinin, of three of its analogues and of caerulein in the dog.
Experientia, , Apr-15, Volume: 36, Issue:4
1980
Effect of acetylcholine, gastrin, and glucagon alone and in combination with secretin and cholecystokinin on the secretion of the isolated perfused rat pancreas.
Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, , Volume: 179, Issue:3
1981
Caerulein and morphine: an attempt to differentiate their antinociceptive effects.
Pharmacology, , Volume: 25, Issue:3
1982
Reassessment of gastric acid inhibition by cholecystokinin and gastric inhibitory polypeptide in dogs.
Gastroenterology, , Volume: 83, Issue:5
1982
Effects of carbachol, cholecystokinin, and insulin on protein phosphorylation in isolated pancreatic acini.
The Journal of biological chemistry, , Sep-10, Volume: 257, Issue:17
1982
In vitro effects of pancreatic polypeptide and motilin on contractility of human gallbladder.
Digestive diseases and sciences, , Volume: 28, Issue:6
1983
Hormonal effects on the pylorus.
The American journal of physiology, , Volume: 243, Issue:5
1982
A new scintigraphic technique for cholecystokinin gallbladder dose-response study: validation in rabbits.
Journal of clinical pharmacology, , Volume: 24, Issue:2-3
[Sonographic study of the effect of hyoscin-N-butylbromide on cholecystokinin stimulated gallbladder motility].
Zeitschrift fur Gastroenterologie, , Volume: 22, Issue:6
1984
Vagotomy does not alter cholecystokinin's inhibition of sham feeding.
The American journal of physiology, , Volume: 246, Issue:5 Pt 2
1984

Interactions (3)

ArticleYear
Effect of acetylcholine, gastrin, and glucagon alone and in combination with secretin and cholecystokinin on the secretion of the isolated perfused rat pancreas.
Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, , Volume: 179, Issue:3
1981
Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry.
Experimental brain research, , Volume: 74, Issue:1
1989
Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: microdialysis combined with a sequential multiple antigen radioimmunoassay.
Neuroscience, , Volume: 45, Issue:1
1991